{"title": "PDF", "author": "PDF", "url": "https://www.insp.mx/images/stories/Centros/cisp/Docs/lim/LIM_Prev_CtrlCancer.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "1 CENTRO DE INVESTIGACI\u00d3N EN SALUD POBLACIONAL LIM EN ACCI\u00d3N: PREVENCI\u00d3N Y CONTROL DE C\u00c1NCER Mayo del 2010 El Fruto de la Investigaci\u00f3n Para la UNESCO, la finalidad esencial de un art\u00edculo cient\u00edfico es \"comunicar los resultados de investigaciones, ideas y debates de una manera clara, concisa y fidedigna, para lo cual, los autores y los jefes de redacci\u00f3n deben poner su m\u00e1ximo esfuerzo para lograr dicho objetivo\". El \u00e9xito obtenido con la publicaci\u00f3n cient\u00edfica una vez que ha pasado la revisi\u00f3n por pares y dem\u00e1s criterios de selecci\u00f3n seg\u00fan la revista que se haya elegido como medio de difusi\u00f3n de los hallazgos y resultados, se compartir\u00e1 con los dem\u00e1s, lo cual generar\u00e1 cr\u00edticas tanto negativas como positivas, controversias, confirmar\u00e1 previos estudios o sentar\u00e1n las bases para investigaciones futuras. Sin embargo, el impacto final de toda investigaci\u00f3n no termina ah\u00ed, sino que debe medirse mediante el uso de t\u00e9cnicas cienciom\u00e9tricas y bibliom\u00e9tricas para el an\u00e1lisis de las citas de estas aportaciones originales. En el CISP del INSP hemos comenzado a trabajar esta parte mediante el estudio de las citaciones a los art\u00edculos publicados con autor\u00eda o coautor\u00eda de la fuerza de investigaci\u00f3n de este centro mediante la recuperaci\u00f3n de una muestra importante de citas a estos art\u00edculos y tomando como base las diferentes l\u00edneas de investigaci\u00f3n del INSP en la cuales participan, con el objetivo de recabar indicadores primordiales como lo son el inter\u00e9s tem\u00e1tico de los investigadores externos tanto nacionales como internacionales, conocer el nombre de las revistas en las cuales son frecuentemente citados, presentar los t\u00edtulos de los trabajos m\u00e1s citados y asimismo conocer el nombre de las revistas que los investigadores eligen para difundir sus hallazgos. Como tercer estudio de la serie \"LIM en Acci\u00f3n\" corresponde publicar el an\u00e1lisis citograf\u00edco de la producci\u00f3n cient\u00edfica de los investigadores del CISP sobre la L\u00ednea de Investigaci\u00f3n por Misi\u00f3n Prevenci\u00f3n y Control del C\u00e1ncer. 2 INDICE EL FRUTO DE LA INVESTIGACI\u00d3N ............... P\u00e1g. 1 INVESTIGADORES LIM - C\u00c1NCER ................. P\u00e1g. 3 DATOS GLOBALES SOBRE EL C\u00c1NCER .......... P\u00e1g. 4-5 AN\u00c1LISIS CITOGR\u00c1FICO TRABAJOS M\u00c1S CITADOS ................. P\u00e1g. 6-8 SOBRE LAS REVISTAS CIENT\u00cdFICAS P\u00e1g. 9-13 TEM\u00c1TICA CON SULTADA P\u00e1g. 14 GEORGE N. PAPANICOLAOU : \"EL LEGADO DE LA ESPERANZA\" ............... P\u00e1g. 15-16 CITOGRAF\u00cdA ................................................ P\u00e1g. 17-115 MUJER Y C\u00c1NCER: MAR\u00cdA EVA DUARTE DE PER\u00d3N .................. P\u00e1g. 116 CR\u00c9DITOS ................................................... P\u00e1g. 117 3 INVESTIGADORES CITADOS DEL CISP: (Orden alfab\u00e9tico) DRA. AHIDEE GUADALUPE LEYVA FLORES DRA. ANG\u00c9LICA ROCIO ANGELES LLERENAS DR. AURELIO CRUZ VALD\u00c9Z DRA. BETANIA ALLEN LEIGH DR. CARLOS A. HERN\u00c1NDEZ GIR\u00d3N DRA. EDNA JUDITH ARILLO SANTILL\u00c1N DR. EDUARDO C\u00c9SAR LAZCANO PONCE DR. EDUARDO SALAZAR MART\u00cdNEZ MTRA. ELSA MAR\u00cdA YUNES D\u00cdAZ DRA. GABRIELA TORRES MEJ\u00cdA LIC. IDANELLI BARRIOS JACOBO DRA. ISABELLE ROMIEU DE HERN\u00c1NDEZ MTRA. LEONOR RIVERA RIVERA DRA. LIZBETH TERESITA L\u00d3PEZ CARRILLO MTRO. FRANCISCO JAVIER L\u00d3PEZ ESPINO Y DE ANTU\u00d1ANO DRA. MA. DE LOURDES GUADA FLORES LUNA DRA. LUISA ELVIRA TORRES S\u00c1NCHEZ DRA. LUISA MAR\u00cdA S\u00c1NCHEZ ZAMORANO DRA. LUZ MYRIAM REYNALES SHIGEMATSU DRA. MARCIA VER\u00d3NICA GALVAN PORTILLO DR. MART\u00cdN MTRA. MA. DEL PILAR HERN\u00c1NDEZ NEVAR\u00c9Z DR. RAYDEL VALD\u00c9S SALGADO 4 DATOS GLOBALES SOBRE EL C\u00c1NCER. En M\u00e9xico el alto \u00edndice de casos relacionados al c\u00e1ncer es considerado un problema grave de Salud P\u00fablica por su alta letalidad y por los diversos factores de riesgo tanto individuales como ambientales, lo que constituye junto con las Enfermedades Cardiovasculares y las complicaciones de la Diabetes Mellitus una de las principales causas de muerte en nuestro pa\u00eds. A continuaci\u00f3n se presentan algunas cifras y datos relevantes a este tema. Conforme al \u00faltimo reporte mundial de c\u00e1ncer 2008 publicado por la OMS fueron 12 millones de casos nuevos de c\u00e1ncer diagnosticados durante ese a\u00f1o, la mortalidad fue de 7 millones por la misma causa y 25 millones de personas viven con esa enfermedad. [1] Para la regi\u00f3n de las Am\u00e9ricas, durante el 2008 el estimado de nuevos casos de c\u00e1ncer fue de 2 617 000; de ellos 1 338 000 correspondieron a hombres y 1 279 000 a mujeres. La mortalidad estimada fue de 1 258 000 muertes, en hombres se calcul\u00f3 en 651 000 defunciones y 607 000 en mujeres. [1] Para la regi\u00f3n espec\u00edfica de Centro, Sudam\u00e9rica y el Caribe el numero total de casos nuevos fue de 1 011 000; con un total 589 000 muertes por esta causa; 302 000 fueron hombres y 287 000 mujeres. El c\u00e1ncer mas incidente en esta misma regi\u00f3n fue el de pr\u00f3stata para los hombres y el de mama entre las mujeres; siendo el de pulm\u00f3n el mas letal para ambos sexos. [1] World Cancer Report 2008. pag 19 El mayor carcin\u00f3geno asociado a las muertes por c\u00e1ncer es el tabaco. [1] Desde el 2006 en M\u00e9xico, entre las neoplasias, el c\u00e1ncer de mama se ha convertido en la principal causa de muerte para las mujeres adultas de entre 30 y 54 a\u00f1os de edad, en ese a\u00f1o se registraron 4 451 defunciones. [2] En 2006 las mujeres en M\u00e9xico con edades entre 30 y 65 a\u00f1os presentaron un riesgo mayor de morir por c\u00e1ncer mamario que por c\u00e1ncer de cuello uterino, mientras que en 1980 el riesgo de morir por este \u00faltimo era 2 veces mayor. [2] La tendencia de Ca de mama en M\u00e9xico ha sido ascendente con una tasa de 5.6 muertes por cada 100 000 mujeres en 1979 a 10.1 en 2006; las tasas mas altas de mortalidad se encuentran en la capital y en el norte del pa\u00eds. [3] 5 En el 2007 se se\u00f1ala al c\u00e1ncer como la tercera causa de muerte entre las mujeres mexicanas con 35 303 defunciones mientras que en los hombres fue la cuarta causa de muerte con un total de 33 509 defunciones; este mismo reporte indica que los 3 principales tipo de c\u00e1ncer que causaron mas muertes en las mujeres fueron el de mama, cuello uterino e h\u00edgado. [4] La primera causa neopl\u00e1sica de muerte en M\u00e9xico en 2007 entre los hombres fue el de pr\u00f3stata, seguido por el de pulm\u00f3n y estomago. [4] El c\u00e1ncer c\u00e9rvico-uterino es el segundo tipo de c\u00e1ncer que afecta a las mujeres entre 15 y 44 a\u00f1os de edad a nivel mundial con 493 243 nuevos casos y 273 505 defunciones anuales. En Am\u00e9rica 86 532 nuevos casos son diagnosticados anualmente por esta enfermedad. [5] En M\u00e9xico el c\u00e1ncer c\u00e9rvico-uterino ocupa el segundo lugar de muertes en mujeres despu\u00e9s del c\u00e1ncer de mama, durante los \u00faltimos 25 a\u00f1os ha causado mas de 100 000 defunciones. [6] La asociaci\u00f3n del virus del papiloma humano con el c\u00e1ncer de cuello uterino es establecida s\u00f3lidamente a trav\u00e9s de muchos estudios en los cuales se ha encontrado el ADN de este virus en el 99.7% de muestras tumorales en distintas zonas de todo el mundo. [7] Hay mas de 100 subtipos del VPH pero los que se encuentran mas frecuentemente asociados (90%) con el c\u00e1ncer cervical son: 16, 18, 45, 31, 33, 52, 58 y 35, de los anteriores, los tipos m\u00e1s comunes son el 16 y el 18 causantes del 70 % de los carcinomas de c\u00e9lulas escamosas y 89% de los carcinomas adenoescamosos; los subtipos de bajo riesgo mas frecuentemente encontrados son el 6 y el 11. [5,7,8] Actualmente existen dos vacunas preventivas disponibles principalmente contra los tipos: VPH 16 y 18 (bivalente); VPH 6, 11, 16 y 18 (cuadrivalente). [6,7,8] Anualmente se producen en las Am\u00e9ricas cerca de 39 000 muertes debido al c\u00e1ncer de cuello uterino de las cuales 33 000 defunciones se presentan en Am\u00e9rica Latina y el Caribe, lo cual indica que la tasa de mortalidad es 7 veces superior a la de Am\u00e9rica del Norte (Estados Unidos y Canad\u00e1); un estudio de 15 a\u00f1os de investigaci\u00f3n presentado recientemente reporta qu e la prevalencia encontrada de VPH es de 20 a 30 % en mujeres de 15 a 24 a\u00f1os de edad, 11% en mujeres de entre 45 y 54 a\u00f1os y de 20% en mujeres de mas de 65 a\u00f1os de edad. [8] 4 La bacteria Heli cobacter pylori y las infecciones de hepatitis v\u00edrica se cons ideran los agentes causales de 2 de los 4 tipos de c\u00e1ncer m\u00e1s mortales para los hombres que son el de est\u00f3mago e h\u00edgado respectivamente . [9] El c\u00e1ncer es la segunda causa de muerte infantil en M\u00e9xico, anualmente 7 000 ni\u00f1os adquieren la enfermedad de los cuales se estima que 1500 mueren por esta causa. La leucemia es el tipo de c\u00e1ncer m\u00e1s com\u00fan en esta poblaci\u00f3n. [10] BIBLIOGRAF\u00cdA 1. World Health Organization. World Cancer Report 2008 . International Agency for Research on Cancer. Lyon France 2008. Dispon ible en:< http://www.iarc.fr/en/publications/pdfs-online/wcr/index.php > 2. FM, Lozano R, Arreola H. G\u00f3mez-Dant\u00e9s H. M\u00e9xico: numeralia de c\u00e1ncer de mama . Competitividad, Salud y Observatorio de la Salud; FUNSALUD. Marzo 2008. 3. Palacio-Mej\u00eda LS, Lazcano-Ponce EC, Allen-Leigh B, Hern\u00e1ndez-Avila M. Diferencias regionales en la mortalidad por c\u00e1ncer de mama y cervix en M\u00e9xico entre 1979 y 2006 . Salud Publica Mex 2009;51(Supl 2):S 208-S219. 4. INEGI. Estad\u00edsticas a prop\u00f3sito del d\u00eda mundial contra el c\u00e1ncer: datos nacionales . M\u00e9xico Febrero del 2009. 5. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and Cervical Cancer in the 2007 Report. 2007 1Nov;25(Suppl 3): C1-230. 6. Lazcano Ponce EC. Salmer\u00f3n Castro J, Garc\u00eda Carranc\u00e1 A, et al . Recomendaciones para la definici\u00f3n de la pol\u00edtica de vacunaci\u00f3n contra el virus del papiloma en M\u00e9xico. Salud Publica Mex 2009 Jul-Ago;51(4):336- 41. 7. Abarca K. Valenzuela MT. Vergara R. et al. Declaraci\u00f3n del comit\u00e9 consultivo de inmunizaciones de la Sociedad Chilena de Infectolog\u00eda respecto a la vacuna anti-virus papiloma humano Rev Chil Infectol 2008;25(6):428-34. 8. OPS/OMS/SV I/CDC. Hacia la prevenci\u00f3n y control integra les del c\u00e1ncer cervicouterino. Regi\u00f3n de las Am\u00e9ricas. Reuni\u00f3n sobre el Virus del Papiloma Humano Ciudad de M\u00e9xico 12 -13 de mayo del 2008. Sabin Vaccine Institute. 9. UICC. Protecci\u00f3n contra las infecciones que provocan c\u00e1ncer . Uni\u00f3n Internacional Contra el C\u00e1ncer 2010. 10. Asociaci\u00f3n Mexicana de Lucha Contra el C\u00e1ncer. C\u00e1ncer Infantil. Consultado el 07 de abril del 2010. Disponible en: <http://www.amlcc.org/elcancer06.html> 6 AN\u00c1LISIS CITOGR\u00c1FICO Se realiz\u00f3 una revisi\u00f3n para obtener el mayor n\u00famero de citas de los investigadores del CISP correspondientes a los a\u00f1os 2008-2009 dando como resultado la obtenci\u00f3n de: 112 trabajos seleccionados de la producci\u00f3n cient\u00edfica del CISP relacionadas a la LIM en estudio 1116 citas a esos trabajos. 866 art\u00edculos que citan esta producci\u00f3n (ver citograf\u00eda ) TRABAJOS M\u00c1S CITADOS En relaci\u00f3n a lo s 112 art\u00edculos, 41 son los que tienen el mayor n\u00famero de citas (6 o m\u00e1s): Tabla 1: Art\u00edculos m\u00e1s citados ART\u00cdC ULOS CITADOS CITAS Villa LL, et al. (The Future II Study Group, Lazcano -Ponce E .) Quadrivalent vaccine NEJM 2007 10Ma of human papillomavirus prevalence in women worldwide: et Int J Canc er 2006 1Dec;119(11):2677 -2684. 56 Reisinger KS. Block SL. o-Ponce Esser Erick J. HL. persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus -like particle vaccine in preadolescents and adolescents - N. Herrero R. Ferrecio C. Wistuba II. de Ruiz PA. Urista GA. Nervi Epidemiology and molecular pathology of CA v-Dec;51(6):349 -64. 37 Lazcano -Ponce E . Herrero R. Mun oz N. Cruz A. Shah KV. Alonso P. Hern\u00e1ndez P . Salmeron J. Hernandez M. Epidemiology of HPV infection with normal cervical cytology. Int J Cancer 2001 1Feb;91(3):412 -20. 28 Berumen J. Ordonez RM. Lazcano E. Salmeron J. Galvan SC. Est rada RA. Yunes E. Garcia -Carranca A. Madrigal -de la Campa A. Asian -American variants of human papillomavirus 16 and risk for cancer: a case -control study. J Natl (17):1325 Herrero R. Molano M. Matos E. Ferreccio PTH. Thomas JO. CJLM. Sexual behavior, use, Snijders PJF. Meijer CJLM. Thomas JO. Anh PTH. Ferreccio de Ricciardi G. Gianfagna F. Ebert MPA. JY. CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro M. Ling D. L. 19 -Pena GA. Luna AL. L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian -Garduno JA. Cruz -Valdez A. Diaz Schiavon R. Hern\u00e1ndez . Hernandez clinics Cancer 2006 -Ponce papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res 2001 May -Jun;32(3):243 -7. 16 L\u00f3pez -Cervantes M. Torres -S\u00e1nchez LM. Gonz\u00e1lez -Lira -Avila M. Dietary factors and endometrial cancer risk. Results of case -control study in Mexico. Int J Gynecol Canc er 2005 Sep -Oct;15(5):938 -45. 15 Lajous E. Hern\u00e1ndez -Avila M. Willett W. Romieu I. Folate, vitamin B -6, and vitamin B -12 intake and the risk of breast cancer 15 Vaccarella Herrero R. Snijders PJF. Dai M. Thomas JO. Hieu NT. Ferreccio C. Matos E. Posso H. de human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 200 8 14 Sicinschi LA. L\u00f3pez -Carrillo L. Constanza -Camargo M. et al. 2006. Gastric cancer Romieu Allen Leonard YF. Lazcano -Ponce EC. et al. The Acceptability of Self - collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & Gender 2002;11(3):265 -Carrillo R. Chili pepper consumption and gastric cancer in Mexico: a case -control J Epidemiol 1994;139:263 -71. 11 Lajous M. Romieu I. Sabia prospective study of French women. Cancer Causes Control 17, 1209 - 1213, 2006. 11 Romieu I. Lazcano -Ponce E. S\u00e1nchez -Zamorano LM. Willett W. Hern\u00e1ndez -Avila Carbohydrates and the st Mexican women. Cancer Epidemiol Biomarkers 8 P\u00e9rez Lazcano -Ponce E. Hern\u00e1ndez -Avila M. Garcia PJ. Mun\u00f3z N. Villa LL. Bryan J. Taddeo FJ. Lu S. Esser MT. Vuoco S. Sattler C. Barr E. Safety, immunogenicity, an d efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus -like-particle vaccine in Latin American women. Int J Canc er 2008 15Mar;122(6):1311 -8. 10 Murillo R. Almonte M Pereira A. Ferrer E. Gamboa OA. Jeronimo J. Lazcano -Ponce E. Cerv ical Cancer Screening the Vaccine 2008 19Aug;2 6(Suppl 11):L37 -L48. 10 Ward MH. and the Risk of Gastric Cancer in Mexico City. Am J Epidemiol 1999;149(10):925 - 9 Salazar -Mar tinez E. Lazcano -Ponce EC. Lira-Lira GG. Escudero -De -Castro J. Larrea F. Hernandez -Avila M.Case -control Leyva A . Uribe M. Manzanares H. Antunez A. Carmona E. Ronnett BM. Sherman ME. Bishai D. Ferris D. Flores Y. Yunes E. Shah KV. Comparison of HPV -based assays with Papanicolaou smears screening Morelos State, Mexico. Cancer Causes Control 20 03 Aug;14(6):505 -12. 9 Hern\u00e1ndez -Gir\u00f3n Smith JS. Lorincz A Lazcano women in Mexico. Sex Transm Dis 2005 Oct;32(10):613 -8. 9 Palacio -Mejia LS. Rangel -G\u00f3mez G. Hern\u00e1ndez M. poverty: Mortality differences between urban and rural areas in Mexico. Salud Publica Mex 2003;45 (Suppl 3):S315 -S325. breast cancer among Mexican women. Cancer Causes Control 8 Lazcano Ponce EC . Najera Aguilar P. Buiatti E. Alonso De Ruiz P. Kuri P. Cantoral L. Hern\u00e1ndez Avila M. The cervical cancer screening program in Mexico: problems with access and -704. I. postmenopausal breast cancer in a prospective study of French J Clin Nutr. 2008;87(5):1384 -1391. 7 Ortega -Altamirano D. L\u00f3pez -Carrillo L. L\u00f3pez -Cervantes M. Estrategias para la ense\u00f1anza del autoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 -25. 7 L\u00f3pez -Carrillo L. Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C. Reyes R et al (1997) dichlorodiphenyltrichloroethane serum levels and breast cancer -3732 6 Giuliano AR. Lazcano -Ponce E Villa Nolan T. Marchant C. Radley D. Golm G. McCarroll K. baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus -like-particle vaccine.. J Infect Dis 20 07 15Oct;196(8):1153 -62. 6 Salazar -Mart\u00ednez E. Lazcano -Ponce EC. Lira-Lira GG. Es . Lazcano GG. Escudero -De -Castro J. -Avila M. Reproductive factors fertility population in Mexico. Cancer Res 1999 1Aug;59(15):3658 -62. No de Citas 6 6 Franco EL. Tsu V. Herrero R. Lazcano -Ponce E. Hildesheim A. Mun\u00f3z N. Murillo R. S\u00e1nchez GI. Andrus JK. Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean. Vaccine 2008 19 Aug;26(Suppl 11):L88 -L95 6 9 SOBRE LAS REVISTAS CIENT\u00cdFICAS I. REVISTAS EN LAS CUALES LOS INVESTIGADORES DE LA LIM EN ESTUDIO FUERON CITADOS. En cuanto a las revistas que fueron mas citadas (Tabla 2 ) derivadas de las 1116 citas a la producci\u00f3n del CISP tenemos como l\u00edder al \"New England Journal of Medicine\" (Estados Unidos) de la \"Massachusetts Medical Soc iey\" con \u00e9nfasis en Medicina Interna. Su alto Factor de Impacto 50.017 la ubica dentro del nivel V y como una de las m\u00e1s importantes publicaciones cient\u00edficas dentro del vasto campo de la Medicina. Otras publicaciones relevantes son: \"The International Journal of Cancer\" (Estados Unidos) revista oficial de la International Union Against Cancer (UICC) con un FI de 4.734 con nivel IV ; \"C\u00e1ncer Epidemiology, Biomarkers & Research\" (Estados Unidos) su FI es de 4.770 - nivel IV; \" Vaccine\" (Holanda) FI de 3.298 - nivel IV y \"Salud Publica de M\u00e9xico\" publicaci\u00f3n oficial del Instituto Nacional de Salud P\u00fablica (M\u00e9xico) con un FI de 0.937 y clasificada dentro del nivel III. Con nivel V mencionaremos a: \"CA: A Cancer Journal for Clinicians\" (Estados Unidos), nal of the National Cancer Institute\" (Estados Unidos), \"Environmental Health Perspectives\" (Estados Unidos) y \"Faseb Journal\" (Estados Unidos) y por parte de Sudam\u00e9rica a la \"Revista de Saude Publica \" (Brasil) con nivel III Tabla 2 Revist as que aparecen con m\u00e1s citas a los trabajos publicados del CISP ( 5 citas o m\u00e1s). REVISTAS CITADAS Citas *Nivel NEW ENGLAND JOURNAL OF MEDICINE 287 V INTERNATIONAL JOURNAL OF CANCER 134 IV CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION 109 IV VACCINE 82 IV SALUD PUBLICA DE M\u00c9XICO 59 III AMERICAN JOURNAL OF EPIDEMIOLOGY 56 IV PEDIATRIC INFECTIOUS DISEASE JOURNAL 51 IV CANCER, CAUSES AND CONTROL 47 IV CA: A CANCER JOURNAL FOR CLINICIANS 37 V ARCHIVES OF MEDICAL RESEARCH 32 III JOURNAL OF THE NA TIONAL CANCER INSTITUTE 25 V ENVIRONMENTAL HEALTH PERSPECTIVES 20 V FASEB JOURNAL 18 V INTERNATIONAL JOURNAL OF EPIDEMIOLOGY 18 IV JOURNAL OF WOMEN\u00b4S HEALTH 16 III INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 15 III SEXUALLY TRANSMITTED DISEASES 13 III CANCER 12 V NUTRITION AND CANCER 9 III REVISTA SAUDE PUBLICA 9 III AMERICAN JOURNAL OF CLINICAL NUTRITION 7 V INTERNATIONAL JOURNAL OF GYNECOLOGY AND OBSTETRICS 7 III JOURNAL OF INFECTIOUS DISEASES 6 IV ONCOLOGY 6 III EUROPEAN JOURNAL OF CANCER 5 IV ** Nivel de la revista seg\u00fan el Factor de impacto por a\u00f1o del JCR 2008 y conforme al criterio de \"Clasificaci\u00f3n Cualitativa d e Revistas Cient\u00edficas Peri\u00f3dicas\". 10 Tabla 3. Distibuci\u00f3n de los 112 art\u00edculos seleccionados de la producci\u00f3n cient\u00edfica de la LIM de acuerdo al nivel de la revista en la que fueron publicados. Revistas de Nivel III Revistas de Nivel IV Revistas de Nivel V 57 art\u00edculos 45 art\u00edculos 10 art\u00edculos Gr\u00e1fico 1. Misma distribuci\u00f3n mas el n\u00famero correspondiente de citas para cada nivel, lo que nos da un total de 1116 citaciones . II. REVISTAS DONDE SE PUBLICARON LOS ART\u00cdCULOS QUE CITARON LA PRODUCCI\u00d3N CIENT\u00cdFICA DEL CISP. Esta secci\u00f3n corresponde al an\u00e1lisis de revistas donde se publicaron los 866 art\u00edculos que citan los trabajos del CISP, aparece en primer lugar \"Vaccine\" (Holanda), especializada en la prevenci\u00f3n de enfermedades y basada primordialmente en el estudio de las vacunas, cuenta con un factor de impacto por a\u00f1o de 3.298 y de acuerdo a la clasificaci\u00f3n cualitativa de revistas cient\u00edficas peri\u00f3dicas se ubica en el nivel IV . Otras con aporte generoso son \"The International Journal of Cancer\" (Estados Unidos); ; \"C\u00e1ncer Epidemiology, Biomarkers & Research\" ya comentadas en el an\u00e1lisis de las revistas citadas. Clasificadas con nivel V podemos mencionar al \"American Journal of Clinical Nutrition\" (Estados Unidos), \"Environmental Health Perspectives\" (Estados Unidos), \"Cancer\" (Estados Unidos), y \"BMJ\" (Inglaterra) y por \u00faltimo, entre las sudamericanas la \"Revista M\u00e9dica de Chile\" de nivel III . (Tabla 4) 0100200300400500600 articulos 57 45 10 citas 195 514 407NIVEL III NIVEL IV NIVEL V 11 Tabla 4 . Revistas donde se publicaron los art\u00edculos que citaron la producci\u00f3n del CISP (5 o m\u00e1s art\u00edculos) REVISTA *Art\u00edculos **Nivel VACCINE 55 IV INTERNATIONAL JOURNAL OF CANCER 32 IV SALUD P\u00daBLICA DE M\u00c9XICO 22 III CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION 17 IV JOURNAL OF INFECTIOUS DISEASES 16 IV GYNECOLOGIC ONCOLOGY 14 III BRITISH JOURNAL OF CANCER 13 IV INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 12 III EUROPEAN JOURNAL OF CANCER 11 IV JOURNAL OF ADOLESCENT HEALTH 10 III SEXUALLY TRANSMITTED DISEASES 10 III CANCER, CAUSES & CONTROL 10 IV AMERICAN JOURNAL OF CLINICAL NUTRITION 9 V JOURNAL OF WOMEN\u00b4S HEALTH 8 III ACTA OB STETRICA ET GYNECOLOGICA SCANDINAVICA 7 III OBSTETRICS & GYNECOLOGY ENVIRONMENTAL HEALTH PERSPECTIVES 7 V ANNALS OF EPIDEMIOLOGY 6 III INDIAN JOURNAL OF MEDICAL RESEARCH 6 III JOURNAL OF MEDICAL VIROLOGY 6 III PREVENTIVE MEDICINE 6 III REVISTA M\u00c9DICA DE CHILE 6 III SEXUALLY TRANSMITTED INFECTIONS 6 III AMERICAN JOURNAL OF EPIDEMIOLOGY 6 IV ANNALS OF ONCOLOGY 6 IV BRITISH MEDICAL JOURNAL 6 V CANCER 6 V AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 5 III EUROPEAN JOURNAL OF CANCER PREVENTIO N 5 III EUROPEAN JOURNAL 5 III EXPERT REVIEW OF VACCINES 5 III PUBLIC HEALTH GENOMICS 5 III JOURNAL OF THE NATIONAL CANCER INSTITUTE 5 V NEW ENGLAND JOURNAL OF MEDICINE 5 V ** Nivel de la revista seg\u00fan el Factor de impacto por a\u00f1o del JCR 2008 y conforme al criterio de \"Clasificaci\u00f3n Cualitativa d e Revistas Cient\u00edficas Peri\u00f3dicas\". 12 Gr\u00e1fico 2 . Distribuci\u00f3n por nivel de la revista de los art\u00edculos que citan la prod ucci\u00f3n cient\u00edfica del CISP (LIM C\u00e1ncer) Gr\u00e1fico 3. Distribuci\u00f3n por reg\u00ed\u00f3n de procedencia de la revista. Con respecto a los pa\u00edses con mayor contribuci\u00f3n de art\u00edculos fueron: Estados Unidos por parte de Am\u00e9rica e Inglaterra y Holanda (en ese orden) por parte de Europa. Las revistas latinoamericanas contribuyeron con 70 art\u00edculos (incluido M\u00e9xico). 8127946442 Nivel VNivel IVNivel IIINivel I-IINIVEL DE LA REVISTAART\u00cdCULOS= OCEAN\u00cdA 55 6% AMERICA 442 51%EUROPA 369 43% 13 Revistas que aparecen en ambas tablas (2 y 4) REVISTA NIVEL AMERICAN JOURNAL OF CLINICAL NUTRITION V AMERICAN JOURNAL OF EPIDEMIOLOGY IV CAN CER EPIDEMIOLOGY, BIOMARKERS & PREVENTION IV AND HEALTH PERSPECTIVES V EUROPEAN JOURNAL OF CANCER IV INTERNATIONAL JOURNAL OF CANCER IV INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER III JOURNAL OF INFECTIOUS DISEASES IV JOURNAL OF THE NATIONAL CANCER INSTITUTE V JOURNAL OF WOMEN\u00b4S HEALTH III NEW ENGLAND JOURNAL OF MEDICINE V SALUD PUBLICA DE M\u00c9XICO III SEXUALLY TRANSMITTED DISEASES III VACCINE IV 14 TEM\u00c1TICA CONSULTADA POR LOS AUTORES QUE CITARON LOS TRABAJOS DEL CISP. www.eleconomista.com.mx Al ser el virus del papiloma humano la etiolog\u00eda principal de c\u00e1ncer cervicouterino, es razonable que las investigaciones en c\u00e1ncer se enfoquen en la prevenci\u00f3n de la transmisi\u00f3n de este agent e causal, despu\u00e9s de analizar los trabajos m\u00e1s citados podemos concluir que el mayor interes entre los investigadores externos quienes citan esta producci\u00f3n son: 1.- El estudio de las vacunas contra el VPH: a) seguridad; b) eficacia e inmunogenicidad - sobre todo de la vacuna cuadrivalente - c) aceptabilidad y d) los estudios de costo-efectividad. 2.- C\u00e1ncer cervico-uterino: a) estudios epidemiol\u00f3gicos; b) mortalidad b) prevalencia del HPV en mujeres; d) prevalencia HPV en hombres. 3.- Factores de riesgo: a) Las variantes asiatico-americanas del HPV-16 y el riesgo de contraer c\u00e1ncer cervical; b) detecci\u00f3n de HPV tanto en mujeres embarazadas como en la no-embarazadas; c) relaci\u00f3n del tabaquismo con la adquisici\u00f3n de la infecci\u00f3n por HPV ; d) comparaci\u00f3n de la mortalidad por c\u00e1ncer cervical asociada a la pobreza en \u00e1reas rurales y urbanas; e) infecciones del HPV relacionadas a conductas sexuales, uso del cond\u00f3n, anticonceptivos orales y factores reproductivos. 4.- Programas de detecci\u00f3n oportuna de c\u00e1ncer: a ) accesibilidad; b) cobertura ; c) aceptabilidad; d) conocimiento; e) las barreras para su implementaci\u00f3n; f) la integraci\u00f3n de las vacunas a los programas nacionales y g) la situaci\u00f3n actual en Latinoam\u00e9rica. 5.- C\u00e1ncer de mama: a) prevalencia; b) la relaci\u00f3n con la exposici\u00f3n al DDT; d) la relaci\u00f3n de este tipo de c\u00e1ncer con la ingesta de carbohidratos, vitamina B6, B12, carga glic\u00e9mica y ag\u00f9nos otros factores diet\u00e9ticos y reproductivos. 6.- C\u00e1ncer g\u00e1strico: a) Helicobacter pylori; b) h\u00e1bitos alimenticios o nutricionales y b) el rol del folato en la carcinog\u00e9nesis g\u00e1strica y la actividad de la enzima MTHFR en este proceso. 7.- La epidemiolog\u00eda y patolog\u00eda molecular del c\u00e1ncer de ri\u00f1\u00f3n tambi\u00e9n se encuentra presente entre los temas m\u00e1s citados. 8.- Los factores de riesgo nutricionales as\u00ed como la relaci\u00f3n de la la obesidad y la diabetes con el desarrollo de c\u00e1ncer de ovario y endometrio tambi\u00e9n estuvieron presentes. 15 \"EL LEGADO DE LA ESPERANZA \" 16 17 CITOGRAF\u00cdA 1) A Brief History of Vitamin D and Cancer Prevention . Mohr SB. Ann Epidemiol 2009 Int J Gynecol Cancer 2005 Sep -Oct;15(5 ):938 -45. 2) A cost -utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Dee A. Howell F. Eur J Public Health. OnLine October 2009. Trabajo (s) citado (s): Insinga RP. Dasbach based evaluation. Vaccine 2007, 26:128-139. 3) A cost-utility vaccination Canadian Anonychuk AM. (s) citado (s): Insinga dynamic based 26:128-139. A Trabajo (s) citado (s): Ortega-Altamirano D. L\u00f3pez-Carrillo L. L\u00f3pez-Cervantes M. Estrategias para la ense\u00f1anza del autoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 -25. 5) A 2009;5(2):14p. Trabajo (s) citado (s): Romero I. Ayala G. Barrios-Jacobo I . Celis H (2000) Time Trends of in Human Populations: Application to a Postban Situation. Ritter R. et al. Environ Health Perspect 1009 Aug;117(8):1280-6 Trabajo (s) citado (s): an influenza Huber VC, Thomas PG, McCullers JA. Vaccine 2009 18Feb;27(8):1192- 200. Trabajo (s) citado (s): Reisinger KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . Pediatr Infect Dis J 2007 vitamin B12 deficiency. Nettina SM. Nurse Practitioner Lajous Romieu I. Sabia S. and postmenopausal prospective of French women. Cancer Causes Control 17, 1209 -1213, 2006. 9) A non -radioactive PCR -SSCP analysis in Colombia. Moreno -Acosta P, Molano M, Huertas A, et al. Virus Genes 2008 Aug;37(1):22 -30. Trabajo (s) citado (s): of papillomavirus 16 and a case-control study. J Natl Cancer Inst 2001 1Sep;93(17):1325-30. 10) A package of primary health care services for comprehensive family-centred HIV/AIDS care and treatment programs in low-income settings. Tolle MA. Trop Med Int Health 2009 Jun;14(6):663- 72. Trabajo (s) citado (s): 18 Franceschi S curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 11) A R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D of human papillomavirus genotypes HPV women. Tornesello ML, Buonaguro L, Izzo S, et al. J Med Virol 2008 Nov;80(11):1959 -65. Trabajo (s) citado of papillomavirus 16 and a case-control study. J Natl Cancer Efficacy of Quadrivalent Human Papillomavirus 2009 Oct;2(10):868 -78. Trabajo (s) citado (s): Giulia no AR . Lazcano-Ponce E. Villa L the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine al. J Epidemiol Commun Health 2009 Jul;63(7):5105. Trabajo (s) cancer screening in a developing country: A randomised field trial . Int J Cancer 15Sep;87(6):869- 73. 15) A randomized controlled trial of calcium plus D supplementation and risk of benign proliferative disease. 2):339 randomised trial of-human-papillomavirus (HPV) in primary cervical screening. Kitchener HC, Almonte M, Gilham C, et al. Health Technol Assess 2009 Nov;13(51):1-+ Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Reisinger KS . Block SL Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents J 2007 Mar;26(3):201-9. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . NEJM 2007 10May;356(19):1915-27. A review of the evidence comparing the human papillomavirus vaccine versus condoms in the prevention of human Miksis Obstetric Gynecologic Neonatal Nursing 2008 May-Jun;37(3):329- 37. Trabajo (s) citado (s): 19 Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine MH. J Health Policy 2008 Apr;29(1):26-31. Trabajo citado (s): Lazcano- Ponce need for technological . Salud Publica Mex 2003;45(Suppl 3):S449-S462. A Polymorphisms and Gastric Cancer Risk. al. 2008; 361 R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D 21) Breastfeeding and Breast Cancer . Yang L, Jacobsen KH. J Health Dec;17(10):1635-45. Trabajo (s) citado (s): Olaya -Contreras P . Rev Saude Publica 1999 Jun;33(3):237- 45. 22) A systematic review of the reporting of Data Monitoring Committees' analysis and early termination in pediatric clinical trials. Fernandes et BMC Pediatrics 2009; 9: 16. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine an Abnormal Papanicolaou Smear CIN 3 (severe dysplasia or carcinoma in of the uterine cervix. Endocervical adenocarcinoma in situ. Goldstein MA, Goodman A, del Carm en MG, et al. NEJM 2009 26Mar;360(13):1337 -44. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine among Latina Mothers . Bair RM, Mays RA, LA, et al. J Pediatr Adolesc Gynecol 2008 Dec;21(6):329 -34. Trabajo (s) citado Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, . Arch Med 2001 May-Jun;32(3):243-7. Zimet GD. vaccine acceptability. Vaccine Journal of and Gynaecology 2009 Mar;116(4):501-10. Trabajo (s) citado (s): Lazcano- Ponce EC. Castro R . Allen B . P . De Ruiz of J Womens Health 2008 Mar -Apr;8(2):98 -103. Trabajo (s) citado (HPV) vaccine among mothers of adolescents in Cuernavaca, . Arch Med 2001 May-Jun;32(3):243-7. Zimet GD. vaccine acceptability. Vaccine vaccination among female university in Hong Wong WCW, Fong B, Chan PKS. Sex health 2009;6(4):264- 71. Trabajo (s) citado (s): 20 Lazcano- Ponce E. Rivera L. (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res 2001 May-Jun;32(3):243-7. 28) Acceptance of Human Papillomavirus Vaccine by Gynecologists in an Urban Setting. Jaspan DM, Dunton CJ, Cook TL. J Low Genit Tract Dis 2008 Apr;12(2):118- 21. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine health screening guidelines. Frangos JE, Alavian CN, Kimball AB. J Am Acad Dermatol 2008 May;58(3):781- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Shvetsov McDuffie K, et al. J infect Dis 2008 1Apr;197(7):957- 66. Trabajo (s) citado (s): Vaccarella et al. Am Fam Physician 2008 15Mar;77(6):852. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Textor Durst Jansen L, et al. Int J Cancer 2008 15Nov;123(10):2343- 53. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine types in samples of pregnant and non -pregnant women . Freitas LB, Pereira CC, J Obstet Gynecol Reprod Biol 2009 Jul;145(1):41 -4. Feb;11(2):120- 32 Trabajo (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- control J 71. Advantages Disadvantages of Current Against HPV. Madrid -Marina V, Torres - Poveda K, Lopez -Toledo G, et al. Arch Med Res 2009 Aug;40(6):471 -7. Sp. Iss. SI Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int J Epidemiol 2008 Jun;37(3):536- 46. 38) Aetiology of Cancer in Asia. Park S, Bae J, Nam BH, et al. Asian Pac J Cancer Prev 2008;9(3):371-80. citado curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 39) African, Asian or Indian enigma, the East Asian Helicobacter pylori : facts or medical myths. Graham DY. et al. J Dig Dis 2009;10:77- 84 Trabajo (s) citado (s): Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. -10 genes. Int. J. Cancer. -657. 40) Age and C . Barquera S. Epidemiologic panorama of stomach cancer mortality in Mexico. Arc h Med Res 2001;32:312 - 7. 41) Age at menarche is not an independent risk factor for high-risk human infections Int J STD AIDS 2008 Jan;19(1):16- 25. Trabajo (s) citado 2005 Oct;32(10):613-8. associated with attainment of menopause in OlaOlorun Lawoyin natural women Mexico City . Int J Gynecol Obstet 1996 May;53(2):159-66. 43) Age at sexual initiation and number of sexual partners in the female Spanish population Results from the AFRODITA survey . de Sanjose S, Cortes X, Mendez C, et al. Eur J Obstet Gynecol Reprod against HPV. Wright TC, Huh et al. Gynecol Oncol 2008 May;109(2):S40-S47. Suppl 1. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine DM, Paavonen J. Vaccine 2008 14Mar;26(Suppl 1):A7-A11. 22 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine human vaccines in the US. Castle PE, Fetterman B, Akhtar I, et al. Gynecol Oncol 2009 Aug;114(2):365- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine RP, et al. Value in Health 2009 Jul-Aug;12(5):697- 707. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine al. Br 51. (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 49) Age-specific prevalence Obstet Gynecol Biol Jun;138(2):194- 8. curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 50) Age-specific prevalence, papillomavirus infections in a cohort of 290 US men. Giuliano AR, Lu BB, Nielson CM, et al. J Infect Dis 2008 15Sep;198 -35. Trabajo in A Global Review. Smith JS, Melendy A, Rana RK, et al. J Adolesc Health 2008 Oct;43(4):S5-S25. Suppl. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . Uribe M . Manzanares H . Antunez A. Mexico . Cancer Causes Control 2003 Aug;14(6):505-12. Lazcano- Ponce Munoz N . Cruz A . Shah KV of papillomavirus 16 and a case-control study. J Natl Cancer Campos case-control study Arch Med Res Flores -Alfaro et al. Salud Publica Mex 2009 Mar - Apr;51(2):134 -40. Trabajo (s) citado (s): 23 Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV cytology . J Cancer 2001 1Feb;91(3):412-20. Hern\u00e1ndez Campos study Med cervical carcinoma in Mexico - Impact of screening, 1980- 1990. Acta Cytol 1996 May-Jun;40(3):506- 12. 53) Alaska native attitudes on cervical cancer, HPV,and the HPV vaccine. Toffolon-Weiss M, Hagan K, Leston J, et al. Int J Circump Health 2008 Sep;67(4):363- 73. Trabajo (s) citado (s): Lazcano- Ponce E. Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med 2001 Maso L, et al. Public Health Nutr 2009 Sep;12(9):1576- 9. Trabajo (s) citado(s): Hernandez-Avila M .Case-control physical in HPV vaccine introduction planning in low-resources settings. Bingham A. et al. The Open Vaccine Journal 2009;2:1- 16 Trabajo (s) citado (s): Zimet GD. of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. 56) An epidemiological study to identify the risk factors with two different types of controls in high-grade cervical including invasive cancer . Sardana et al. Eur J Cancer Care 2009 Nov;18(6):620- 4. Trabajo (s) citado cancer control . Rev Saude Publica 2000 Apr;34(2):113-9. 57) An of human vaccine clinical trial results. Schiller JT, X, Villa LL, et al. Vaccine 2008 19Aug;26(Suppl 10):K53-K61. Trabajo (s) citado (s): Reisinger KS . Block Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents L the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 51. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine in community-based sample of homosexual men. Vajdic CM, van Leeuwen MT, Jin F, et al. Sex Transm Infect sep;85(5))330- 5. Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 60) Analysis of content about sexuality and human reproduction in school textbooks in Spain . de Irala J, Urdiain IG, del Burgo CL. Public Health 2008 Oct;122(10):1093-1103. Trabajo (s) citado (s): 24 Vaccarella S papillomavirus-associated cervical pathogenesis. Wang XD, Zhuang J, Xie ZY, et al. Rev Med Microbiol 2009 Apr;20(2):33- 40. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine economic data for Italy. Mennini FS, Costa S, Favato G, et al. Vaccine 2009 29May;27(Suppl 1):A54-A61. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against coste -efectividad de vareniclina (Champix) frente a los parches de nicotina en el tratamiento del tabaquismo en M\u00e9xico. Mould- Quevedo JF. Contreras -Hern\u00e1ndez I. PharmaEconomics Spanis L . Ju\u00e1rez-M\u00e1rquez S. Valdez-Salgado R . Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo en el IMSS, Morelos. Salud P\u00fablica Mex 2005; 47: 451- 7. Reynales-Shigematsu L . Rodr\u00edguez-Bola\u00f1os RA. Jim\u00e9nez JA. Ju\u00e1rez-M\u00e1rquez S. Castro-R\u00edos A. Hern\u00e1ndes-\u00c1vila M. Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo en el Instituto Mexicano del Seguro Social. Salud P\u00fablica Mex 2006; 48(supl 1):S48-S64 Salmer\u00f3n-Casto J. Franco-Marina F. Salazar-Mart\u00ednez E . et al. Panorama epidemiol\u00f3gico de la mortalidad por c\u00e1ncer en el Instituto Mexicano del Seguro Social: 1991-1995. Salud Publica Mex 1997;39(4):266- 73 64) Analysis of T -cell proliferation and cytokine secretion in the individuals R. et al. Hum Exp Toxicol 2008;27:381 -6 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of Dis 106 Trabajo (s) citado(s): Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. J. Cancer. 118:649 -657. 66) Annual disease burden due of papillomavirus 16 and a case-control study. Natl Cancer Inst Annual burden of papillomavirus 16 and a case-control Natl Cancer Inst et al. Cancer Causes Control 2009 Jul;20(5):699- 711. Trabajo (s) Int J Gynecol Cancer 2005 Sep -Oct;15(5 ):938 cancer vaccine. GD, Shew ML, Kahn JA. Annu Rev Med 2008;59:223- 36. Trabajo (s) citado (s): 25 Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine with vitamin 12? AD. Am J Clin Nutr 4. Trabajo (s) a population -based cohort study in rural Bangladesh. Sohel N. et al. Epidemiology 2009 Nov;20(6):824 -30 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Banerjee N. et al. Toxicology 2008 18Apr;246(2 -3):101 -11 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of D. et al. Toxicology 2009 Jun;260(1 -3):132 -41 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebr ian ME. 2006. Assessment of lymphocyte and cytokine primary cervical screening. Kitchener HC, Almonte M, Gilham C, et al. Health Technol Assess 2009 Nov;13(51):1+ Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 75) Asia Pacific: Cervical Cancer Screening and Human Papillomavirus Vaccination Policy and Delivery. Shah KV. Vaccine 26 19Aug;26(Suppl 12):III-IV. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine J Vaccine 2006 31Aug;24(Suppl 3);201- 9. 77) Assessing participation of women in a cervical cancer screening program in Peru . Robles SC, Ferreccio C, Tsu V, et al. Rev Panam Salud Publica 2009 Mar;25(3):189 -95. Trabajo (s) citado (s): cancer screening program in a developing country . Arch Med Res 2002 May-Jun;33(3):295-300. .. Rev Saude Publica 2003 Feb;37(1):100-6. Lazcano- Ponce EC. Castro R . Allen B . P . De Ruiz of J Womens Health 78) Assessment of average exposure to organochlorine pesticides in southern Togo (Vigna unguiculata) . Part A Chem Anal Control Exp Risk Epidemiol 2000 15Aug;152(4):363- 70. 26 79) Association between a pro -inflammatory genetic older adults from Germany. Gao L. et al. Eur J Cancer 2009 Feb;45(3):428 -34 Trabajo (s) citado (s): Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. genes. Int. J. Cancer. 118:649 -657. 80) Association between human papillomavirus DNA load and development of cervical intraepithelial neoplasia and cervical cancer . Huang Y, Huang MN, Li N, et al. Int J Gynecol Cancer 2008 Jul-Aug;18(4):755-60. Trabajo (s) citado (s): Diagnost 2009;4:39 (s) citado (s): S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. JY. CM. T. F. Lacasa\u00f1a -Navarro D et TR. et al. J Rheumatol 2009 Jul;36(7):1501 -6. Trabajo (s) citado (s): Trejo -de OA north Indian population. Pandey SN, Choudhuri G, Mittal B. Eur J Cancer Prev 2008 Apr;17(2):77- 81. Trabajo (s) citado the risk of gastric cancer: a case -control study in Hawaii. Epplein M. et al. Cancer Causes Control 2008;19:869- 77 Trabajo citado G. Ram\u00edrez-Espitia Ward L. Dietary Factors and the Risk of Gastric Cancer in Mexico City. Am J Epidemiol 1999;149(10):925- Association of severity in cervical 354 women in a US population. Zuna RE, Moore WE, Shanesmith RP, et al. Int J Cancer 2009 1Dec;125(11):2609- 13. Trabajo (s) citado of papillomavirus 16 and a case-control study. et al. . J Dis Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R 27 87) the North Pacific Ocean and the adjacent Arctic region: Spatial distribution, congener patterns and X. et al. Atmosph 2009 Sep;43(28):4319- 26 Trabajo (s) citado (s): L\u00f3pez M. Torres -S\u00e1nchez L girls potential role of in the i mmunization Madhivanan P, Krupp K, Yashodha MN, et al. Vaccine 2009 20Aug;27(38):5203 -8. Trabajo (s) citado (s): Lazcano- Ponce E. Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med 2001 Determinants of Human Papillomavirus Vaccine Acceptability in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L73-L79. 90) Augmented serum level of major histocompatibility complex -related chain A (MICA) protein and reduced NKG2D expression on NK and T cells and precursor lesions et al. BMC Cancer 2008 21Jan;8:Artic 16. Trabajo (s) citado (s): Lazcano-Ponce S de MH cancer screening in developing countries: Why is it ineffective? The case of Mexico . Arch Med Res 1999 May-Jun;30(3):240-50. 91) Automation of the linear array HPV genotyping test and its application for routine typing of human papillomaviruses in cervical specimens abnormalities in Switzerland. Dobec al. J Clin Virol 2009 May;45(1):23- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM breast cancer in Mexico . Moh ar A, Bargallo E, Ramirez MT, et al. Salud Publica Mex 2009;51(Suppl 2):S263 -S269. Trabajo of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. 94) Background Review Paper on Total Fat, Fatty Acid Intake and Cancers. Gerber M. Ann Nutr Lajous breast cancer in a prospective study of French women. Am J Clin Nutr. 2008;87(5):1384 -1391. 95) Barreras de acceso al diagn\u00f3stico temprano del c\u00e1ncer de mama en el Distrito Federal y en Oaxaca. Nigenda G. et al. Salud Publica Mex 2009;51(supl 2):S254-S262. Trabajo (s) citado (s): de M\u00e9xico, to vaccine Vaccine 31Aug;24(Suppl 3);201- Self-sampling for Papillomavirus across Ethnolinguistic Groups of Women. Howard M. Lytwyn A. et al. Canadian Journal of Public Health-Revue Canadienne De Sante Publique 2009; -D\u00edaz E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acceptability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & d vaginal samples. Ferreccio C, Corvalan A, Margozzini P, et al. BMC Public Health 2008 28Feb;8:78. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Dzuba IG. Yunes -D\u00edaz E. Allen B. YF. Lazcano- Ponce EC. et al. The Acceptabili ty of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & and 6, 16, 18 young German women participating phase al. Arch Gynecol Obstet 2009 Jun;279(6):803- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Opin Jun;24(6):1623- 34. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine (s): Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D et Pharmacol 2008;60(6):803 -8 Trabajo (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- control 1994;139:263- 71. 103) Biomarkers of oxidative stress and damage in human populations exposed to arsenic. De Vizcaya -Ru\u00edz A. et al. Mutat Res 2009 Mar;674(1,2):85 -92 Trabajo (s) citado (s): M\u00e9ndez -G\u00f3mez J. Garc\u00eda -Vargas GG. L\u00f3pez -Carrillo L. Calder\u00f3n- Aranda ES. G\u00f3mez A. Vera E. Valverde M. Cebri\u00e1n ME. Rojas E. Genotoxic Effects of environmental exposure to arsenic and lead on children in region Lagunera, Mexico, NY Acad. Sci 2008;1140:358 -67. 104) Breast Cancer ERS, et J Surg 2009 Oct;33(10):2069-76. Trabajo (s) citado Lozano R, et al. Reprod Health Matt 2008 Nov;16(32):113- 123. Trabajo (s) M. et al. Identificaci\u00f3n de lesiones mamarias en M\u00e9xico. Salud P\u00fablica de M\u00e9xico 2001;43(3):199 -202. Ortega-Altamirano D. L\u00f3pez-Carrillo L. L\u00f3pez-Cervantes M. Estrategias para la ense\u00f1anza del autoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 -25. Poblano-Verastegui O. Figueroa-Perea JG. L\u00f3pez 106) cancer trends in Latin America and the Caribbean . Lozano -Ascencio R, Gomez -Dantes H, Lewis S, et al. Salud Publica Mex 2009;51(Suppl 2):S147 -S156. Trabajo (s) citado Jul Breast cancer : why in developing countries? Et Salud Publica Mex 2009;50(suppl 2):S220-S227 Trabajo (s) citado (s): Bernstein J. L\u00f3pez-Carrillo L. L. Epidemiology of Her-2/neu Reproductive determinants of breast cancer in Mexican women. Ann N Y Acad Sci 1997; 837:537-50. 108) Breast- feeding Antunes LAA, al. Ciencia Saude Colectiva 2008 Jan -Feb;13(1):103 -9. Trabajo (s) citado (s): Olaya -Contreras P . . Gajalakshmi V, Mathew A, Brennan P, et al. Int J Cancer 2009 1Aug;125(3):662- 5. Trabajo (s) citado (s): Romieu lactation (s) -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Ce brian M. Rueda C. Reyes R et al (1997) dichlorodiphenyltrichloroethane serum levels and breast cancer 70. HIV Association guidelines for HIV-associated malignancies 2008. Bower M, Collins S, Cottrill C, et al. HIV Med 2008 Jul;9(6):336- 88. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Papillomavirus Infections and Related Diseases in the Latin America and Caribbean Region . Parkin DM, et al. Vaccine 2008 19Aug;26(Suppl 11):L1 -L15. Trabajo (s) citado (s): Murillo R . Almonte M Pereira A . . E. Cervical Screening Programs in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48. P\u00e9rez G . Garcia and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8. Flores -Luna 30 113) Burden of Invasive Squamous Cell Carcinoma of the Penis in the United States, 1998-2003. Hernandez BY, Barnholtz-Sloan J, German RR, et al. Cancer 91. Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R -51 Trabajo (s) citado (s): S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. JY. CM. T. F. Lacasa\u00f1a -Navarro D vaccination? Challenges to vaccine implementation. Garland SM. Ind J Med Res 2009 Sep;130(3):311- 21. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 DNA self -collected vaginal samples compare with sician -collected developing countries? N, L, Patro AR, et al. Epidemiol 2009 Dec;33(6):446 -50. . Uribe M . Manzanares H . Antunez A. Mexico (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Cancer cervico-uterino asociado al embarazo. Reporte de un caso. Urdaneta J. Zambrano NB. Contreras-Benitez A. Rev Chil Obstet Ginecol Mexico . Sex Transm Dis 2005 Oct;32(10):613-8. 119) C\u00e1ncer de mama en M\u00e9xico: una prioridad apremiante. Knaul FM. Et al. Salud Publica Mex 2009;51 (supl 2):S335-S344 . L\u00f3pez-Cervantes M. et al. Identificaci\u00f3n de lesiones mamarias en M\u00e9xico. Salud P\u00fablica de M\u00e9xico M. Estrategias para la ense\u00f1anza del autoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 -25. Poblano-Verastegui O. Figueroa-Perea JG. L\u00f3pez et al. Lancet Oncol May;9(5):473- 84. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Cancer research - then and now. Bode AM, Dong ZG. Nat Rev Cancer 2009 Jul;9(7):508- 16. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Future. Lippman SM. Cancer Prev Res 2009 Jun;2(6):503- 13. 31 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine From 1727 to Milestones of the Past 100 Years. Lippman SM, Hawk ET. Cancer Res 2009 1Jul;69(13):5269- 84. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and 2009;21(3):665- 71 (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- 71. 126) Carbohydrate of postmenopausal in a prospective study of French women . Lajous M, Boutron-Ruault MC, Fabre A, et al. Am J Clin Nutr 2008 May;87(5):1384- 91. Trabajo Case and the risk of endometrial endometrioid adenocarcinoma . Koizumi T, Nakaya N, al. Eur J Cancer Prev 2008 Aug;17(4):358 -63. Trabajo (s) Int J Gynecol Cancer 2005 Sep -Oct;15(5 Anorlu RI. Reprod Health 2008 (s): -Mejia LS of poverty: Mortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325. 129) Cervical cancer and HIV in Africa: a review. Ouattara S. Some DA. Bambara M. Da B. J Afr Cancer 2009;1:110 -4 Trabajo citado Jeronimo J . New Approaches to Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58. 130) Cervical cancer review. Firnhaber CS. Michelow P. South Afr J HIV Med 2009 Jul;34:23- 7. Trabajo (s) citado (s): Lazcano- Ponce role of human papillomavirus vaccines in India. Bhatla N, Joseph E. Ind J Med Res 2009 Sep;130(3):334- 340. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine attitudes and intentions. al. J Adv Nurs of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. 32 133) Cervical Cancer Prevention in the Human Papilloma Virus Vaccine Era. Ghazal-Aswad S. An NY Acad Sci 2008;1138:253- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Oncol 2008 Jan;5(1):12 -13. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Birth in the US-Mexico Border Region, 2005: The poverty: Mortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Supl 3):S315-S325. 136) Cervical Cancer Screening the Early Postvaccine Waxman AG. Obstet Gynecol Clin North Am 2008 Dec;35(4):537. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and population-based study . Chao A, Hsu KH, Lai CH, et al. Int J Cancer 2008 15Jun;122(12):2835- 41. Trabajo (s) citado (s): Vaccarella curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 138) Cervical cancer: Screening and therapeutic perspectives. Sankaranaraya nan R, Thara S, Esmy PO, et al. Med Princip Pract 2008;17(5):351 -64. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine A. Gynecol Oncol 2008 Suppl. 2. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Sexual Behavior: Collaborative Reanalysis of Individual Data on 15,461 Women with Cervical Carcinoma and 29,164 Women without Cervical Carcino ma from 21 Epidemiological Studies . Appleby M. L\u00f3pez -Carrillo L. De Ru\u00edz PA. Torres -Lobat\u00f3n A. Gonz\u00e1lez -Lira A. Romieu I. Reproductive factors and sex life -history and cervical -cancer in Mexico City. Rev Invest Clin 1995 Sep - Oct;47(5):377 -85. 33 142) Cervical carcinoma in Southern Mexic o: Human papillomavirus and cofactors Hern\u00e1ndez -Avila M. L\u00f3pez -Carrillo L. De Ru\u00edz PA. Torres A. Gonz\u00e1lez A. Romieu Reproductive factors and sex life -history and cervical -cancer in Mexico City. Rev Invest Clin 1995 Sep - Oct;47(5):377 -85. Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV poverty: Mortality differences between urban and rural areas Mexico Publica Mex 2003;45(Suppl Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The cervical cancer screening program Mexico: problems infection and HPV type 16 antibodies in South African women. Marais DJ, Constant D, Allan B, et al. J Clin Microbiol 2008 Feb;46(2):732- 9. Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 144) Cervical screening according to age and HPV status. G, Arbyn M, curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 145) CCR5 Delta Immunol 2008 May;67(5):516- 22. Trabajo (s) citado Ponce in S, et al. Curr 61. (s) citado curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 147) Characterization S, et 50. citado of papillomavirus 16 and a case-control study. J Natl exposure from CCA-treated wood. Baptist PL. et al. Leslie NS. J Nurs Pract 2008 Jan;4(1):48- 53 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian gallbladder cancer. Srivastava et al. J Gastroenterol Hepatol 2008 Jun;32(6):970 -5. Trabajo (s) citado Hypoth cancer A study in Japan. Yagyu Kikuchi S, Obata Y, et al. Int J Cancer 2008 15Feb;122(4):924- 9. Trabajo (s) citado (s): Lazcano- Ponce et al. J Clin Immunol 2009 Sep;29(5):582 -94 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of of Immune Response Genes in Mouse Lung. KOzul CD. et al. Environ Health Perspect 2009 Jul;117(7):1108 -15 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of al. . J Infect Dis 2008 15Mar;197(6):787- 94. Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R Ward Dietary Factors and the Risk Gastric Cancer in Mexico City. Am J Epidemiol 1999;149(10):925- Classification of Cancer Recurrence with Alpha-Beta Acevedo ME, F. Math Probl Engineer 2009 Article Number: trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. Tay EH, Garland S, Tang G, et al. Int J Gynecol Obstet 2008 Oct;102(3):275- 83. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and Schiller et al. Lancet Infect Dis 2009 Jun;9(6):347- 56. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Choi Kim JW, Khang SK, et al. Kor J Pathol 2009 Oct;43(5):441- 7. 35 Trabajo (s) citado (s): Lazcano-Ponce Hernandez-Avila M .Case-control physical et al. Am J Obstet Gynecol 2009 Feb;200(2):130- 5. Trabajo (s) Hernandez-Avila M .Case-control physical J on human papillomavirus PKS. H K. Hong Kong J Dermatol Venereol 2008;16(1):12- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Debicki D, et 2008 15Sep;26(Suppl 5):F16 -F28. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine immunogenicity and safety of Cervarix (TM) and Gar dasil (R) papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18 -45 years. Einstein MH. Baron M. et al. Human Vaccines 2009; 5(10): 705 -719. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and behaviors regarding (s) citado (s): Ortega-Altamirano D. L. L\u00f3pez-Cervantes M. Estrategias para la ense\u00f1anza del autoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 -25. 165) Comparison of two PCR-based human papillomavirus genotyping methods. Castle et al. J Clin Microbiol 2008 Oct;46(10):3437- 45. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazca no-Ponce E. ). Quadrivalent Polymorphisms 167) Cancer in North Indian Population. Srivastava A, Mittal B. Scand J Immunol 2009 Dec;70(6):614- 20. Trabajo (s) citado Ponce Filippova M, Filippov VA, Ka goda M, et al. J Virol 2009 1Jan;83(1):210 -27. Trabajo (s) citado of papillomavirus 16 and a case-control study. J Natl Cancer Inst 2001 1Sep;93(17):1325-30. 169) Conglomerados de c\u00e1ncer g\u00e1strico en el estado de M\u00e9rida, Venezuela. Alonso-Amelot ME. Avenda\u00f1o-Meza M. Interciencia 2009 Sep;34(9):617- 22 Trabajo (s): 36 Ward MH. L\u00f3pez-Carrillo L. Dietary Factors and the Risk of Gastric Cancer in Mexico City. Am J Epidemiol 1999;149(10):925- 32. 170) Conocimientos, aceptabilidad y actitudes sobre la vacuna contra el VPH en m\u00e9dicos generales, ginec\u00f3logos y pediatras en Colombia. Pi\u00f1eros M. Cort\u00e9s C, et al. Rev Colomb Cancerol 2009;13(2):88- 98 Trabajo (s) citado (s): Franco EL . Tsu V. Herrero R . Lazcano-Ponce E . Hildesheim Vaccination and Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 19 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Hahn et al. Int J Gynecol Cancer 2009 Aug;19(6):1068- 73. Trabajo (s) citado . population Mexico . Cancer Res 1999 1Aug;59(15):3658- of sweet foods and breast cancer risk: a case-control study of women on York . PT, Sagiv Mexican women . Cancer Causes Control of cervical cancer in Colombia: the perspective of the health system . Wiesner-Ceballos C, Moreno RHM, Petersen MP, et al. Rev Panam Salud Publica 2009 Jan;25(1):1- 8. Trabajo (s) citado (s): Lazcano-Ponce EC . Najera Aguilar P . Buiatti Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The cervical cancer screening program Mexico: problems to the organochlorine / total lipids ratio. Porta M. et al. Environ Int 2009;35:1080-5 Trabajo (s) citado (s): Verner -43. Sex 2005 Oct;32(10):613-8. Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV . Int J Cancer 2001 1Feb;91(3):412-20. 178) Cost -effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Colantonio L, Gomez JA, Demarteau N, et al. Vaccine 2009 4Sep;27(40):5519 -29. Trabajo (s) citado (s): 37 Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV . Int J Cancer 2001 1Feb;91(3):412-20. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . Uribe M . Manzanares H . Antunez A. Mexi Causes J Gynecol Obstet 2001 Oct;75(1):33-42. 179) Cost -effectiveness analysis of adding a quadrivalent HPV vaccine to 2008 May;24(5):1473-83. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Hernandez-Avila M .Case-control physical Causes Control Cost of human papillomavirus-vaccination programs to prevent cervical cancer in Austria . Zechmeister I. et al. Vaccine 2009 Aug;27(37):5133- 41 Trabajo (s) citado (s): Insinga RP. Dasbach based evaluation. Vaccine 2007, 26:128-139. 182) Cost -Effectiveness analysis of human papillomavirus Vaccination in the Netherlands . de Kok IM. et al. J Natl Cancer Inst 2009;101(15):1083- 92. Trabajo (s) citado based Vaccine 2007, 26:128-139. 183) Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Kim JJ, Goldie SJ. BMJ 2009 8Oct;339 Article Number: b3884 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of the introduction of a quadrivalent human papillomavirus vaccine in France. Bergeron C, Largeron N, McAllister R, et al. Int J Technol Assess Health Care 2008 Win;24(1):10- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Papillomavirus Vaccine in Belgium. L, Remy V, Oyee J, et al. Pharmaeconomics 2009;27(3):231- 45. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine A, Sanchez -Gonzalez G, Bautista -Arredondo S, et al. Salud Publica Mex 2009 51(Supl 2):S296 -S304. Trabajo (s) citado Mar-Apr;50(2):119-25. 187) Cost -effectiveness of cervical cancer screening with DNA testing and HPV-16,18 vaccination. Goldhaber-Fiebert JD, Cancer Inst 2008 5Mar;100(5):308- 20. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and Cervical Cancer Screening in Women Older Than 30 Years in the United States. Kim JJ, Ortendahl J, Goldie SJ. Ann Intern Med 2009 20Oct;151(8):538- 45. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine in Belgium: Do not forget about cervical cancer screening. Thiry N, De Laet C, Hulstaert F, et al. Int J Tech Assess Health Care 2009 Apr;25(2):161-70 - Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Usher C, Tilson L, Olsen J, et al. Vaccine 2008 16Oct;26(44):5654- 61. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Vaccine 2007, 26:128-139. 191) Cost -effectiveness of cervical cancer: A multi-regional analysis scenarios. Suarez E, JS, Bosch FX, et al. Vaccine 2008 15Sep;26(Suppl 5):F29-F45. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . NEJM 2007 10May;356(19):1915-27. 192) Cost of screening and treatment of cervical dyskaryosis in Germany. Petry KU, Breugelmans JG, Benard S, et al. Eur J Gynaecol Oncol 2008;29(4):345- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . NEJM 2007 10May;356(19):1915-27. 193) Costo institucional del infarto agudo del miocardio en en el Instituto de Cardiolog\u00eda y Cirug\u00eda Cardiovascular. Fern\u00e1ndez-Garcia A. et al. Rev Cub Salud Publica;43(4):1-7 Trabajo (s) citado (s): Reynales-Shigematsu L . Ju\u00e1rez-M\u00e1rquez S. Valdez-Salgado R . Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo en el IMSS, Morelos. Salud P\u00fablica Mex 2005; 47: 451- 7. 194) Costs and benefits of HAART for patients with HIV in a public hospital in Mexico . Aracena -Genao B, Navarro JO, Lamadrid -Figueroa H, et al. AIDS 2008 Jul;22(Suppl 1) of cervical cancer among Mexican women . Salud Publica Mex 2000 May-Jun;42(3):242- 51. 195) Coverage of Cervical Cytology and Related Colombia . al. Cancerol 2008 ;12(3):119 -125 Trabajo (s) citado (s): Murillo R . Almonte M Pereira A . . E. Cervical Screening Programs in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48. 196) Country recommendations on 2006 -January 2008. Koulova A, Tsui J, Irwin K, et al. Vaccine 2008 2Dec;26(51):6529 -41. 39 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Current challenges and future perspectives in the medical treatment of solid tumours. Sobrero A, Di Benedetto M. Eur JCancer SUPPLEMENTS 2008 Oct;6(14):91-3. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine immunization. Brabin L, Greenberg DP, Hessel L, et al. Vaccine 2008 5Aug;26(33):4120 -34. Trabajo (s) citado (s): Lazcano- Ponce E. Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, . Arch Med 2001 May-Jun;32(3):243-7. Zimet GD. of vaccine Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . Pediatr 2007 Mar;26(3):201-9. 200) Current status of gynecological cancer in China. Kim K, Zang R, Choi SC, et al. J Gynecol Oncol 2009 Jun;20(2):72 -6. Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 201) Current Understanding . citado KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents J 2007 Mar;26(3):201-9. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine PV. Infect Dis 2008 15Mar;197(6):781- 3. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Schiavon R (s): L. Constanza-Camargo M. et al. 2006. genes. Int. J. Cancer. 118:649 -657. 40 205) DDT Perspect 2008 Apr;116(4):A153 L\u00f3pez -Cervante s M. Torres -S\u00e1nchez L respond . Cohn BA, Cirillo Sholtz RI, et al. Health Perspect to evaluate cervical cancer in era of HPV vaccination. Howlett RI, Miller AB, Pasut G, et al. . Prev Med 2009 May;48(5):432- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine infection . Harris L, Am J Obstet Gynecol 2009 May;200(5):Article 489.e1. Trabajo (s) citado the Van Harmont D, Bekkers RLM, Massuger LFAG, et al. Rev Med Virol 2008 Mar-Apr;18(2):117- 32. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine papillomavirus vaginal samples of women in Chiang Mai, Thailand. Wongworapat K. Keawvichit R. et al. Sex Transm Trabajo (s) citado -D\u00edaz E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acce ptability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & Gender . Uribe M . Manzanares H . Antunez A. Mexico Causes et al. Sex Transm Dis 2009 Mar;36(3):149- 56. Trabajo (s) citado (s): Developing a Nigerian-specific food and nutrient coding database. Day RS. et al. J Food Composit Anal 2008 Feb;21(Suppl 1):S109-S114 Trabajo (s) citado women. Cancer 2002;43(2):133- 40 41 214) Development of an Adenoviral Vaccine Against E6 and E7 Oncoproteins to Prevent Growth of Human Papillomavirus-Positive Cancer. Lee DW, Anderson ME, Wu S, et al. Arch Otolaryngol Head Neck Surg 2008 Dec;134(12):1316- 23. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine enhanced tortillas . Scazzina F, Del Rio D, Serventi L, et al. Food Biophys 2008 Jun;3(2):235- 40. Trabajo citado . evaluation of effects of other known risk f actors . Saltzman BS, Doherty JA, Hill DA, et al. Am J Epidemiol 2008 1Mar;167(5):607 -14. Trabajo (s) citado (s): E . F . Hernandez-Avila M .Case-control physical 70. L . Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C. Reyes R et al (1997) dichlorodiphenyltrichloroethane serum levels and breast cancer -Sanchez L, Galvan -Portillo M, Lewis S, et al. Salud Publica Mex 2009;51(Supl 2):S181 -S190. Trabajo (s) breast cancer risk in Mexican women . Salud Publica Mex Mar- Apr;50(2):126-35. Mexican women . Torres -Sanchez L, Galvan - Portillo M, Wolff MS, et al. Public Health 2009 Jun;12(6):825.31. Trabajo (s) citado et al. Cancer Causes breast cancer in postmenopausal women: the National Institutes of Health - AARP Diet and Health Study. Park Y. et al . Am J Clin Nutr 2009;90:664 -7 Trabajo breast cancer in a prospective study of May-Jun:20(3):9- 12 Trabajo (s) citado (s): Lajous M. breast cancer in a prospective study of Nutr. 2008;99(7):1170.5 Trabajo citado Lajous breast cancer in a prospective study of Nutr. et al. Cancer and Risk of Cancer: A Prospective Cohort Study. George SM. et al. Am J Epidemiol 2009;169(4):462-72. Trabajo (s) citado (s): Lajous M. breast cancer in a prospective study of . Dal Maso M, et al. Cancer Causes Control 2008 Dec;19(10):1209 -15. Trabajo (s) Int J Cancer Breast ncer: A Case -Control Study in Japan. Ma Enbo. et al. Nutr Cancer 2009;61(4):447 -56 Trabajo (s) citado Lajous Sabia S. and postmenopausal prospective of women. Causes Control 17, 1209 2006. women. Ma Enbo. BMC 2009 24Apr;9:122 Trabajo (s) citado Lajous Sabia and postmenopausal prospective of French women. Cancer Causes Control 17, 1209 -1213, 2006. citado (s): Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert JY. CM. intakes and omega -3 polyunsaturat ed fatty acids and the risk of breast cancer. Thiebaut ACM. et al. Int J Cancer -931 Trabajo (s) citado (s): Lajous and postmenopausal prospective of French women. Causes Control 17, 1209 -1213, 2006. 233) Dietary breast cancer risk in American women . Wu AH, Yu MC, Tseng CC, et al. Am J Clin Nutr 2009 Pharmacol 2008;52(4):327 -54 (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- control study. Am J Epidemiol 1994;139:263- 71. 235) Differences in the risk of cervical cancer and human papillomavirus infection by education level. Franceschi S, Plummer M, Clifford G, et al. Br J Cancer 2009 25Aug;101(5):865-70. Trabajo (s) citado (s): Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV . Int J Cancer 2001 1Feb;91(3):412-20. Murillo R . Almonte M Pereira A . E. Cervical Screening Programs in Latin America and the Caribbean . Vaccine 2008 11):L37-L48. 236) Interact 2009;180:485- 91 Trabajo (s) -S\u00e1nchez L al, Environ Res 2009;109:22 -8 Trabajo (s) citado (s): Verner testing as an alternative for cervical cancer prevention. Barata PC. Mai V. J Psychosom -D\u00edaz E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acceptability of Self -collected Samples for HPV Testing vs. the Pap Test as A lternatives in Cervical Cancer Screening. Journal of Women's Health & of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 240) Distribution with Cancer in Mongolia. Chimeddorj B, Pak CY, Damdin A, et al. Asian Pac J Cancer Prev of papillomavirus 16 and case-control study . J Natl invasive cervical cancer in Italy: A institution case series. Sideri M, Cristoforoni P, Casadio C, et al. Vaccine 2009 29May;27(Suppl 1):A30-A33. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM Papillomavirus Type 58 Variants in Progression of Cervical Dysplasia in Korean Women. Bae JH, Cheung JLK, Lee SJ, et al. J Microbiol Biotechnol 4. Trabajo of papillomavirus 16 and a case-control study. J Natl Cancer Inst 2001 Distribution of human warts of men. (s): . Lazcano-Ponce Castro Schiavon R J Cancer 2006 15Oct;119(8):1934-9. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 Distribution human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes over the last decades. Chan PKS, Ho WCS, Yu MY, et al. Int J Cancer 2009 1Oct;125(7):1671- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine on HPV vaccination?: no. Lippman Scurfield C. Can Physician 2008 Feb;54(2):175,177, 179,181. Block Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and Expression in Human from U.S. Population. Andrew AS. et al. Environ Health Perspect 2008 Apr;116(4):524- 31 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian CP. et al. J Drug Targeting 2009;17(6):474- 89 Trabajo (s) citado (s): Bernstein J. L\u00f3pez-Carrillo L. Wang L. Epidemiology of Her-2/neu Res 2009 1Mar;15(5):1814- 20. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM Early Experience with Human Papillomavirus Vaccine Introduction in the United States, Canada and Australia. Shefer A, Markowitz L, Deeks S, et al. Vaccine 2008 19Aug;26(Suppl 10):K68-K75. Trabajo (s) citado (s): 45 Reisinger KS . Block SL . Lazcano-Ponce E et Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. 250) Ecological Studies Of Ultraviolet B, Vitamin D And Cancer Since 2000 . Grant WB, Mohr SB. Ann Epidemiol 2009 Jul;19(7):446 -54. (s) Human Papillomavirus Vaccination Developed Countries. Brisson M, Van de Velde N, Boily MC. . Public Health Genom 2009;12(5-6):343- 51. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of human papillomavirus vaccination in the United Kingdom. Choi YH, WJ. BMJ 2009 9Aug;337(7665): Article:a769. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine vaccination: Within-study and gained . Puig-Junoy 26:128-139. 254) Edible compounds as antitumor agents. Mohammad A. et al. Indian J Sci Technol 2009;2(5):62- 74 Trabajo (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- control study. Am J Epidemiol 1994;139:263- 71. 255) Educational level and cervical cancer a area . N\u00fanez J, J, Mindiola R, et al. Clin 2008 Sep;49(3):331 -9. Trabajo (s) citado (s): Lazcano-Ponce EC . Najera Aguilar P . Buiatti Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The cervical cancer screening program Mexico: problems cancer screening program in a developing country . Arch Med Res 2002 May-Jun;33(3):295-300. 256) Effect of arsenic on tegulatory T Cells. Hern\u00e1ndez -Castro B. et al, J Clin Immunol 2009;29:461 -9 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et Assessment of lymphocyte sub and cytokine Lipid Metabolism. Yeun -Seok Y. et al. Korean J Fam Med 2009;30:790 -5 Trabajo (s) citado (s): Lajous M. Boutron-Ruault breast cancer in a prospective study of Anandakumar P. et al. Nat Prod Res 2009;23(8):763- 74 Trabajo (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- control study. 1994;139:263- 71. 46 259) Effect of Genetic Predisposition on Risk of Gallbladder Cancer in Hungary. Kimura A, Tsuchiya Y, Lang I, et al. Asian Pac J Cancer Prev 2009;9(3):391- 6. Trabajo Results of a Randomized Controlled Trial Conducted in Orange Farm, South Africa. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. . J Infect Dis 2009 1Jan;199(1):14- 9. Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R Pregnancy Invest 2009;67(3):208 -16. Trabajo Plant Brreding 2009;7(3):586- 90 Trabajo (s) citado (s): Oliva G. Romero I. Ayala G. Barrios-Jacobo I . Celis H (2000) Papillomavirus Vaccine Systematic Review . Marra F. et al. 2009;27(2):127- (s) citado (s): Insinga based Vaccine 2007, 26:128-139. 264) Effectiveness of Cultivando La Salud: A Breast and Cervical Cancer Screening Promotion Program for Low- Income Hispanic Women . Fernandez ME, Gonzales A, Tortolero-Luna G, et al. Am J Public Health 2009 May;99(5):936-43. Trabajo (s) citado (s): Aguilar -Perez JA 265) of cytology cervical cancer screening in Colombian health system . Murillo R, Cendales R, Wiesner C, et al. Biomedica 2009 Se p;29(3):354 -61. Trabajo (s) citado (s): Lazcano-Ponce EC. Moss S de MH cancer screening in developing countries: Why is it ineffective? The case of Mexico . Arch Med Res 1999 May-Jun;30(3):240-50. Hern\u00e1ndez -Avila M . ca se-control Int J Epidemiol Jun;27(3):370- 6. 266) Effects of in utero arsenic exposure on child immunity and morbidity in rural Bangladesh. Raqib R. et al. Toxicol Lett 2009 Mar;185(3):197-202 Trabajo (s) citado (s): Soto -Pena GA. Lun a AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of Vaccine 2006 31Aug;24(Suppl 3);2 01-9. 47 268) Effects of Peer and Group on Knowledge, Beliefs and Breast Self -Examination Practice among University Students in Turkey. Karayurt O. et al. Turk J Med Sci 2009;39(1):59 -66 Trabajo (s) citado (s): Ortega-Altamirano D. L\u00f3pez-Carrillo L. L\u00f3pez-Cervantes M. Estrategias para la ense\u00f1anza del autoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 -25. 269) Effects of the Esteban MA. Fish Shellf Immunol 2008 Nov;25(5):682 -8. Data and HPV Vaccination Studies (Reply). Haug C. JAMA 2009 23Dec;302(24):2659 -60. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine ines A Systematic Quantitative Review. Medeiros LR, Rosa DD, da Rosa MI, et al. Int J Gynecol Cancer 2009 Oct;19(7):1166 -76. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents immunity and cross protection after HPV vaccination: A review of the evidence. Bonanni P, Boccalini S, Bechini A. Vaccine 2009 29May;27(Suppl 1):A46-A53. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 10May;356(19):1915-27. El virus del papiloma humano y el c\u00e1ncer cervicouterino. Castellanos Morales MR. Rev Fac Med UNAM 2004;47(1):35 -36. Trabajo (s) citado (s): Dzuba IG. Yunes -D\u00edaz E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acceptability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & Gender -Based in Exfoliative Cells Cancer . Ding citado MH cancer screening in developing countries: Why is it ineffective? The case of Mexico . Arch Med Res factors. Linkov F, Edwards R, Balk J, et al. Eur J Cancer 2008 Aug;44(12):1632- 44. Trabajo (s) citado Int J Gynecol Cancer 2005 Sep -Oct;15(5 ):938 -45. 276) Enhancement of underused cervical cancer prevention services in rural Oaxaca, Mexico . Givaudan M, Leenen I, Pick S, et al. Rev Panam Salud Publica 2008 Feb;23(2):135- 43. Trabajo (s) citado (s): Lazcano-Ponce EC . Najera Aguilar P . Buiatti Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The cervical cancer screening program Mexico: problems an early detection program of cervical cancer in the state of M orelos . Salud Publica Mex 1999 Jul-Aug;41(4):278- 85. 277) ENT update seminar Comprehensive further training over 2 days. Ayazpoor U. HNO 2009 Feb;57(2):178 -80. Trabajo (s) citado (s): 48 Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine on function a nd development. Petri WA. et al. J Clin Invest 2008 apr;118(4):1277 -90. Trabajo (s) citado (s): Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. -657. 279) Entire genome characterization of human with different cytological findings. Lurchachaiwong W, Junyangdikul P, Payungporn S, et al. Virus Genes 2009 Aug;39(1):30- 8. Trabajo (s) citado (s): of papillomavirus 16 and a case-control Weyandt Ellsworth RE, Hooke JA, et al. Curr Med Chem 2008 Nov;15(26):2680-2701. Trabajo -S\u00e1nchez Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C. Reyes R et al (1997) dichlorodiphenyltrichloroethane serum levels and breast cancer Aug;16(8):2101- 15. clinical of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model . Insinga RP, Dasbach EJ, Elbasha EH. BMC Infect -Luna L Oct;75(1):33-42. 283) Epidemiologic Risk Profile of Infection Different Groups of Human Papillomaviruses. Chan PKS, Ho WCS, Wong MCS, et al. J Med Virol 2009 Sep;81(9):1635- 44. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Vaccarella S 2009 Jul-Aug;32(4):281- Trabajo citado . et al. Eur J Gynaecol Oncol 2008 29(2):114-22. Trabajo (s) citado (s): 49 curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Lazcano- Ponce E. Herrero R. Munoz N . Cruz A . Shah KV . . Int J Cancer 2001 1Feb;91(3):412-20. 286) Epidemiology and cost of treatment of warts in Spain. Castellsague X, Cohet C, Puig-Tintore LM, et al. Eur J Public Health 2009 Jan;19(1):106- 110. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine al. Trabajo (s) citado (s): based evaluation. Vaccine 2007, 26:128-139. 288) Epidemiology and Natural History Papillomavirus M, et 19Aug;26(Suppl 10):K1-K16. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 289) Epidemiology and Prevention of Human Papillomavirus and Cervical in and Mongolia . Shi JF, Qiao YL, Smith JS, et citado tract cancers: an update. Randi G, Malvezzi M, Levi F, et al. Ann Oncol 2009 Jan;20(1):146- 59. Trabajo (s) citado (s): Lazcano- Ponce Health Genom Trabajo (s) citado (s): Giuliano AR . E . Villa M papillomavirus infection papillomavirus prevalence and type distribution among men residing in Brazil, and the Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6. 292) Espacios 100% libres de humo : una realidad en el Distrito Federal. Guillermo-Tenorio X. Salud Publica Mex 2008;50(Supll 3):S384-S390 Trabajo (s) citado Reynales- Jim\u00e9nez JA. Ju\u00e1rez-M\u00e1rquez S. Castro-R\u00edos A. Hern\u00e1ndes-\u00c1vila M. Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo en el Instituto Mexicano del Seguro Social. Salud P\u00fablica Mex 2006; 48(supl 1):S48-S64 Vaccination in Taiwan. Yen MS, You SL, Ferko N, et al. Int J Gynecol Cancer 2009 Feb;19(2):281- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 10May;356(19):1915-27. 50 294) Estudio piloto: costos directos atribuibles al tabaquismo en dos hospitales de Santiago. Mart\u00ednez-Guti\u00e9rrez MS. et al. Rev Med Chile 2008;136:1281-7 Trabajo (s) citado (s): Reynales-Shigematsu L . Ju\u00e1rez-M\u00e1rquez S. Valdez-Salgado R . Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo en el IMSS, Morelos. Salud P\u00fablica Mex 2005; 47: 451- 7. 295) Ethical and social implications of the introduction of the vaccine against the human papilloma virus in Mexico: Reflections on a proposed intervention. de la Rosa AP, Delgado CG, Klip DF, et al. Acta Bioethica 2008;14(2):157-65. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Elath care workers. Valdez E, P, Bedolla M, et al. Ethics 2008 Nov;15(6):729 -44. Trabajo citado (s): . and arthritis in Mexico . Med 2004 Ene-Feb;35(1):66- Ethnic in cytokine gene polymorphisms: 2008;57:107- Trabajo (s) citado (s): L. Constanza-Camargo M. et al. 2006. J. Cancer. al. Cancer 2009 15Nov;125(10):2246 -2255. Trabajo (s) citado (s): Franco EL . Tsu V . Herrero R . Lazcano- Ponce E . Hildesheim Vaccination and Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95. Supplement: Suppl. 11 19 2007 roadmap - Conclusion. Wheeler CM, Franceschi S. Vaccine 2008 14Mar;26(Suppl 1):A28-A31. Trabajo (s) citado(s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine vaccines. Chang YL, Brewer NT, Rinas AC, et al. Vaccine 2009 9Jul;27(32):4355- 62. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine S. vaccine Vaccine 31Aug;24(Suppl Kemp TJ, Garcia Falk RT, et al. Vaccine 2008 4Jul;26(29 -30):3608 -16. Trabajo (s) citado(s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of cervicouterine cancer\" program . Llanos AA, Salas MM. Atencion Primaria 2009 Jun;41(6):300- 5. Trabajo (s) citado (s): Lazcano-Ponce EC. Moss S an early detection program of cervical cancer in the state of Morelos . Salud Publica Mex 1999 Jul-Aug;41(4):278- 85. 51 304) Evolution of the health economics of cervical cancer vaccination. Ferko N, Postma M, Gallivan S, et al. Vaccine 2008 15Sep;26(Suppl 5):F3-F15. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against Tissue . Fischer D, Thome M, Becker S, et al. Anticancer Res 2009 Sep;29(9):3635- 9. Trabajo (s) citado (s): E . gallbladder. et al. Ann Pathol 2008 Jun;12(3);161- 4. Trabajo (s) citado low-resource settings. Bingham A. Bishop A. Coffey P. et al. Salud Publica Mex 2003;45 Suppl 3:S408- 16 Trabajo (s) citado (s): -D\u00edaz E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acceptability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & Gender -Based -275. Infection in a Cohort of US Men: A Prospective Study. Lu B, Wu Y, Nielson CM, et al. J Infect Dis 2009 1Feb;199(3):362- 71. Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R 309) risk of progression to precursor lesions or cervical cancer in women women in Mexico . Salud Publica Jan-Feb;50(1):49- 58. 310) False for J N atl Cancer Inst 2008 16Jul;100(4):988 -95. Trabajo (s) citado (s): L\u00f3pez M. Torres -S\u00e1nchez L Perspect. and the risk of gastric cancer. Yaghoobi M. et al. Br J Trabajo (s) citado (s): Sicinschi L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acceptability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health Oct;90(4):911- 40 Trabajo (s) citado (s): 52 L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L Labastida -Almendaro S. Breast J 2009 Nov -Dec;15(6):623 -31. Trabajo (s) control . Rev Am 1Feb;89(2):624 -633 Trabajo (s) citado and postmenopausal prospective of women. Control 17, 1209 tale chameleons . Mason Case-Control E, Palma A, et al. Nutr Cancer 2009;61(5):617 -28. (s) Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int J Epidemiol 2008 Jun;37(3):536- 46. 320) Food groups and alcoholic beverages and the risk of stomach cancer: a Italy. Lucenteforte E. (s): Ward Dietary Factors and the Risk Gastric Cancer in Mexico City. Am J Epidemiol 1999;149(10):925- 32. 321) Food groups and study from Italy . Bravi L, Bosetti J Obstet Gynecol 2009 Mar;200(3): 293.e1. Int J Gynecol Cancer 2005 Sep-Oct;15(5):938-45. 322) Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials. Franceschi S, Clifford GM. Int J Cancer 2008 1Feb;122(3):719- 20. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine to - The Example of Cervical Cancer: My Personal Contribution to This Fascinating History. Mun\u00f3z N. Public Health Genom 2009;12(5- 6):368-71. Trabajo (s) citado (s): Franco EL . V . Herrero R . Lazcano- Ponce E . Hildesheim Vaccination and Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95. 324) Fumonisin exposure and the sphinganine/sphingosine ratio in uri ne, serum and buccal cells in adults from Burkina Faso, West Africa. Nikiema PA. et al. World Mycotoxin J 2008 Nov;1(4):483 -91 Trabajo (s) citado (s): Gong YY. Torres -S\u00e1nchez L. L\u00f3pez -Carrillo L. Peng JH. Sutcliffe AE. White KL. Humpf HU. Tur ner PC. Wild CP. (2008) Association between tortilla consumption and human urinary LJG. et al. Anal Bioanal Chem 2009 Trabajo (s) citado (s): Gong YY. L. L\u00f3pez -Carrillo L. Peng JH. Sutcliffe AE. White KL. Humpf HU. Turner PC. Wild CP. (2008) Association between tortilla consumption and human urinary for cancer in a North Indian population. Srivastava K, Srivastava A, Pandey SN, et al. J Gastroenterol 2009 Ju l;44(7):774 -80. Trabajo (s) citado (s): Lazcano- Ponce EC. Miquel 2008 1Dec;98(7):485- 9. citado a comprehensive review. Lai ECH, Lau WY. Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2008 Apr;6(2):101- 10. Trabajo (s) citado (s): Lazcano- Ponce EC. Perdue DG, Stewart SL, et al. Cancer 2008 1Sep;113(5):1266- 73. Trabajo (s) citado (s): Lazcano- Ponce et al. Am J Surg 2008 Aug;196(2):252 -64. Trabajo (s) citado (s): Lazcano- Ponce 2009 J Cancer 2009 Aug;48(5):269 -76. Trabajo (s) citado (s): Torres F. Ebert MPA. Fang JY. Gao CM. Gotze T. G raziano F. Lacasa\u00f1a -Navarro Ling D phase II study. Andre T, Reyes -Vidal JM, L, et al. Br Recipients. Garcia-Pineres AJ, Hildesheim A, Dodd L, et al. J Immunol 2009 1Feb;182(3):1706- 29. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine cervical cancer in Mexican women: Results of a Markov model from the public sector perspective . Gutierrez -Delgado C, Baez -Mendozo C, Gonzalez -Pier E, et al. Salud Publica Mex 2008 Mar -Apr;50(2):107 -18. Trabajo (s) citado (s): Salmeron . Uribe M . Manzanares H . Antunez A. Mexico . Cancer Causes Control 2003 Aug;14(6):505-12. Lazcano- Ponce . Allen B . P . De Ruiz of of Japan and Hungary. Nagahashi M, Ajioka Y, Lang I, et al. World J Gastroenterol 2008 7Jan;14(1):70- 5. Trabajo (s) citado (s): Lazcano- Ponce candidate genes. Dong LM. et al. JAMA 2008;299(20):2423- 6. Trabajo (s) citado (s): Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D pathway. Hazra A. et al. Hum Mol Genet 2009 Trabajo (s) citado (s): Galv\u00e1n -Portillo MV . Cant oral A. O\u00f1ate -Oca\u00f1a LF. Chen J. Herrera -Goepfert,R. Torres - S\u00e1nchez L. Hern\u00e1ndez - Ramirez RU. Palma -Coca O. L\u00f3pez -Carrillo L. (2009) Gastric cancer in road ahead. Jim\u00e9nez -S\u00e1nchez G. et al. Genome Res 2008 Aug;18(8):1191 -8 Trabajo (s) citado (s): Lacasa\u00f1a-Navarro M. Galv\u00e1n-Portillo (s): Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro M. D . L. . Hunter La Merrill M, et al. Mammalian Genome 2008 Mar;19(3):179- 89. Trabajo Int J Gynecol Cancer 2005 Sep -Oct;15(5 ):938 Prevalence Herpesvirus de S, Mbisa G, Perez-Alvarez S, et al. J Infect Dis 2009 15May;199(10):1449-56. Trabajo (s) citado (s): Andia ME, Hsing Andreotti G, et al. Int J Cancer 2008 15Sep;123(6):1411- 6. Trabajo (s) citado (s): Lazcano- Ponce access to HPV vaccination: what are we waiting for? Clifford GM. Lancet 2009 12Dec;374(9706):1948- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine expression in Bourdonnay E. et al. Mol Immunol 2009 feb;46(4):649- 56 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of lymphocyte subpopulations cytokine secretion J 20(6):779 -781. 347) Global Epigenetic Cancer Health Disparities in High-Risk Population Groups. Guerrero-Preston R. P R Health Sci J 2008 Dec;27(4):350- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Gnagnarella P, Gandini al. Am J Clin Nutr 2008 cancer risk . Randi G, Ferraroni M, Talamini R, et al. Ann Oncol 2008 Feb;19(2):380 -3. Trabajo citado cancer risk in a prospective cohort of Swedish women. Larsson SC. et al. Int J Cancer 2009;125:153- 7. Trabajo (s) citado (s): 56 Lajous M. breast cancer in a prospective study of J Clin Nutr. Mexican women . Cancer Causes Good girls do ... get vaccinated: HPV, mass marketing and moral dilemmas for sexually active young women. Polzer J, Knabe S. J Epidemiol Commun Health 2009 Nov;63(11):869- 70. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 with a quadrivalent HPV vaccine in Italy. Mennini FS, Rossi PG, Palazzo F, et al. Gynecol Oncol 2009 Feb;112(2):370- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine economic implications of HPV vaccination in the United States. Kim JJ, Goldie SJ. NEJM 2008 21Aug;359(8):821- 32. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 72 GAVI -eligible countries. Goldie SJ, O'Shea M, Campos NG, et al. Vaccine 2008 29Jul;26(32):4080 -93. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM and cervical cancer screening among older women in Latin American and Caribbean citie s. Reyes -Ortiz CA, Velez LF, Camacho ME, et al. Int J Epidemiol 2008 Aug;37(4):870 -8. Trabajo (s) citado (s): Hern\u00e1ndez case-control study . Int J Epidemiol 1998 Jun;27(3):370- 6. 357) Health systems and immunization financing for human papillomavirus vaccine introduction in low -resource settings. Biellik R, Levin C, Mugis ha E, et al. Vaccine 2009 19Oct;27(44):6203 -9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine citado (s): Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Subramaniam D, et PLoS One 2009 3Sep;4(9):Article e6859. gallbladder and extrahepatic biliary tract . de Martel C, Plummer M, Parsonnet J, et al. Br J Cancer 2009 13 Jan;100(1):194- 9. Trabajo A Convoluted Saga. Smith A. Epidemiology 2008;19:24-6 Trabajo (s) citado (s): Tovar -Guzm\u00e1n V. Hern\u00e1ndez -Gir\u00f3n C. Barquera S. Rodr\u00edguez -Carrillo L.. Epidemiologic panorama of stomach cancer mortality in Mexico. Arch Med Res 2001;32:312 - 7. 364) High frequency of multiple HPV types in cervical specimens from Danish women. Mejlhede N, Bonde J, Fomsgaard A, PMIS Feb;117(2):108 -14. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 365) High prevalence of human papillomavirus infection in the female population of Guatemala. Valles X, Murga GB, Hernandez G, et al. Int J Cancer 2009 1Sep;125 (5):1161 -7. Trabajo (s) citado curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. P\u00e9rez G . Lazcano and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8. Vaccarella samples RM, Zhao CQ. 61. Trabajo Ponce E. Herrero R . Munoz N . Cruz A . Shah KV . M, Moysich KB, Jayaprakash V, et al. J Nutr 2009 Feb;139(2).317- 22. Trabajo (s) citado Int J Gynecol Cancer 2005 Sep -Oct;15(5 ):938 -45. HIV subsequently developed oral report of 2 al. J Int Assoc Physicians AIDS Care 2008 Nov-Dec;7(6):306- 10 Trabajo (s) Reisinger KS . Block SL . Lazcano-Ponce E et Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and RH, et al. Gynecol Oncol 2008 Mar;108(3):641- 51. Trabajo (s) citado . population Mexico Res 1999 Hormones and gallbladder cancer in women. Barreto SG. Haga H. Shukla PJ. Indian J Gastroenterol 2009 Jul - Aug;28(4):126 -30. Trabajo (s) citado (s): Lazcano- Ponce EC. (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine HPV vaccine side effects and influence on completion of the three-dose regimen Reiter PL, Brewer NT, Gottlieb SL, et al. Vaccine 2009 16Nov;27(49): 6840 -4. Trabajo (s) citado (s): P\u00e9re z G. E Garcia PJ and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8. 373) How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Coupe VMH, de Melker HE, Snijders PJF, et al. Vaccine 2009 13Aug;27(37):5111- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 2):S47-S48. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine de Sanjose S. Br J Cancer 2008 8Jan;98(1):15- 21. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 2009; 78: 39- 42. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine M, Hussain S, Nasare V, et al. Ind J Med Res 2009 Sep;130(3):327 -33. Trabajo (s) citado (s): Reisinger KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and 2007 Mar;26(3):201-9. HPV vaccine acceptability in a rural Southern area. Fazekas KI. Brewer NT. et al. J Womens Health 2008; 539-548. SK, Wheeler CM, et al. Vaccine 2008 2Dec;26(52):6844- 51. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. 380) HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines. Samara RN, Khleif SN. Curr Mol Med 2009 Aug;9(6):766- 73. Trabajo (s) citado (s): Villa LL, et al. (The Future II Study Group, Lazcano-Ponce E.). Quadrivalent vaccine against human papillomavirus in south Italy. Capra G, Giovannelli L, Bellavia C, et al. Virus Re s 2008 May;133(2):195 -200. Trabajo (s) citado (s): Vaccar ella S . Castro Schiavon R C, Bourgault-Villada I, Coursaget P.Press Med 2009 Dec;38(12):1750- 68. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Vaccarella 384) HPV infection in Europe. De Vuyst H, Clifford G, Li N, et al. Eur J Cancer 2009 Oct;45(15):2632-9. Sp. Iss. SI. Trabajo (s) citado (s): Franceschi S curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 385) HPV infection in women with and without cervical cancer in Conakry, Guinea. Keita N, Clifford GM, Koulibaly M, et al. Br J Cancer 2009 30Jun;101(1):202- 8. Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 386) HPV information needs, from country with multiethnic populations. Wong LP. Vaccine 2009 25Feb;27(9):1410- 5. Trabajo (s) citado (s): Lazcano- Ponce E. Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, . Arch Med 2001 May-Jun;32(3):243-7. Zimet GD. vaccine . Benevolo M, Mottolese M, Marandino F, et al. J Med Virol 2008 Jul;80(7):1275 -81. 60 Trabajo (s) citado (s): Lazcano- Ponce E. R . Munoz cervical cancer: for in a Infect Dis Obstet Gynecol 2009;2009:653598. Epub 2009 Dec 20 Trabajo (s) citado (s): Franco EL . Tsu V. Herrero R . Lazcano- Ponce E . Hildesheim A Vaccination and Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95 DR. Cancer (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and Lizano M, Berumen J, Garcia -Carranca A. Arch Med Res 2009 Aug;40(6):428 -34. Sp. Iss. SI. Trabajo (s) citado (s): of papillomavirus 16 and a case-control Natl Intraepithelial Neoplasia. Kahn JA. NEJM 2009 16Jul;361(3):271- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and sexually active Paepke S, et al. Geburtshilfe Und Frauenheilkunde 2008 Jan;68(1):27- 30. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of cancer epidemiology. Zechmeister I. et al. J Public Health Online Aug 2009 Trabajo (s) citado (s): Insinga RP. Dasbach EJ. Elbasha Vaccine 2007, 26:128-139. 394) HPV vaccination: the beginning of the end of cervical cancer? A Review. Lepique AP, Rabachini T, Villa LL. Mem Inst Oswaldo Cruz 2009 Feb;104(1):1- 10. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and promise & problems. Sankaranarayanan R. Ind J Med Res 2009 Sep;130(3):322- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of US and Salvadoran Populations. Podolsky R, Cremer M, Atrio J, et al. J Pediatr Adole s Gynecol 2009 Aug;22(4):205 -15. Trabajo (s) citado Lazcano- Ponce Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res 2001 May-Jun;32(3):243-7. 397) HPV Vaccine Acceptance among Latina Mothers by HPV Status. Sanderson M, Coker AL, Eggleston KS, et al. J Womens Health 2009 Nov;18(11):1793- 9. Trabajo (s) citado (s): Lazcano- Ponce E. (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res 2001 May-Jun;32(3):243-7. 398) HPV cancer. Bosch 51. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine answer?. Stanley M. Br Med Bull 2008 Dec;88(1):59-74. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and . Gissmann L. Arch Med Res 2009 Aug;40(6):466-70. Sp. Iss. SI. Trabajo (s) citado (s): Giuliano AR . Lazcano -Ponce E. the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. 401) HPV Vaccines: Today and in the Future. Moscicki AB. J Adoles Health 2008 Oct;43(S4):S26-S40. Trabajo (s) citado Reisinger KS . Block SL Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents J 2007 Mar;26(3):201-9. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine VMH, van Ginkel J, de Melker HE, et al. Int J Cancer 2009 15Feb;124(4):970- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Associated With Human Cervical Cerda -Flores Juarez al. Int J Gynecol Cancer 2009 -1106. Trabajo of papillomavirus 16 and case-control study. J Natl Cancer N . Cruz A . Shah KV . Int J Cancer 2001 1Feb;91(3):412-20. 404) Human papilloma Prevention and treatment . Diaz ML. Obstet Gynecol Clin North Am 2008 S and esophageal carcinoma in a Latin -American region . Herrera -Goepfert R, Lizano M, Akiba al. World J Gastroen terol 2009 7Jul;15(23): 7. women in Mexico . Salud Publica Mex 2009 Jan-Feb;50(1):49- 58. Giuliano AR . Lazcano- Ponce E . Villa M papillomavirus infection papillomavirus prevalence and type distribution among men residing in Brazil, and the Cancer Epidemiol Biomarkers N . Cruz A . Shah KV . 2001 1Feb;91(3):412-20. 406) (s) . Lazcano-Ponce Castro Schiavon R adolescence infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int J Epidemiol 2008 (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res 2001 May-Jun;32(3):243-7. 408) Human papilloma virus (HPV) infection in child ren and adolescents. Mammas Sourvinos G, Spandidos DA. Eur J Pediatr 2009 Mar;168(3):267 -73. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine men who have sex with men . Kreuter A, Wieland U. Curr Opin Infect Dis 2009 14. Trabajo (s) citado (s): Giuliano AR . Lazcano- Ponce E. Villa LL papillomavirus prevalence and type distribution among men residing in Brazil, and the United States Cancer Epidemiol Biomarkers Prev Sep;32(3):989- 97. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine a KJ, Bermudez al. Rev Invest Clin 2008 Sep -Oct;60(5):414 -20. Trabajo (s) citado (s): Flores Y . Bishai Results Study . Salud Publica 2003;54(Suppl 3):S388-S398. Lazcano- Ponce Herrero R . Munoz N Cruz A . Shah KV cytology . Int J Cancer 2001 1Feb;91(3):412-20. 63 412) (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and neck region: review of literature. Mannarini L, Kratochvil V, et al. Acta Otorhino Ital Jun;29(3):119 -26. Trabajo . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. and vaccination initiation among in the National Immunization Survey-Adult 2007. Jain N, Euler GL, Shefer A, et al. Prev Med 2009 May;48(5):426- 31. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine vaccination development of public policies. Lippman A. J Epidemiol Commun Health 2008 Jul;62(7):570- 1. Trabajo (s) citado KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents 2007 Mar;26(3):201-9. 416) Human Papillomavirus and Cervical Cancer - Current Status of Vaccination Against Human Pathogenic Papillomavirus In Reply. Loning M, Hillemanns P. Deutsches Arzteblatt Int 2008 7Jan;105(1-2):23- 4. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and Cervical - Current Status of Vaccination Against Human Pathogenic Papillomavirus Low Efficacy . Hirte Arzteblatt Int 7Jan;105(1- 2):22. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine R. Clin Gynecol 2008 - 305. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Clin Proceed 2008 Jun;83(6):701 -7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Klein KC. Am J Health Syst Pharm 2008 15Nov;65(22):2105- 12. Trabajo (s) citado (s): Reisinger KS . Block SL. Lazcano-Ponce E . et Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents J 2007 Mar;26(3):201-9. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Cancer in India: Results from a Multi-center Study. Basu P, Roychowdhury S, UD, et al. Asian Pac J Cancer Prev 2009;10(1):27-34. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine with CIN2/3 cervical cancer - The EDiTH III study. Pretet JL, Jacquard AC, Saunier M, et al. Gynecol Oncol 2008 Aug;110(2):179- 84. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Tornesello Losito S, et al. Int J Cancer 2008 1Jan;122(1):132- 7. Trabajo (s) citado of papillomavirus 16 and a case-control study. tissue tropism? Castle PE. J Infect Dis 2008 1Mar;197(5):776- 8. Trabajo citado 31. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Hematol Oncol Am Dec;22(6): 1125. S infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int J Epidemiol and related LK, Shroyer KR. Pathol 2008 Feb;39(2):154- 66. Trabajo (s) citado (s): Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV J Cancer 2001 1Feb;91(3):412-20. 428) Human papillomavirus and cervical cytology in women screened for the United States, 2003-2005. Datta SD, Koutsky LA, Ratelle S, et al. 2008 1Apr;148(7):493-500. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677- 2684. 429) Human papillomavirus prevention of cervical cancer. Lowy DR, Solomon D, Hildesheim A, et al. Cancer 2008 1Oct;113(7):1980 -93. Sp. Iss. SI. Trabajo (s) citado (s): Franceschi S . curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Republic China: Zhao et al. Br J Cancer 2009 27Oct;101(9):1635- 40. Trabajo (s) citado R infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. 70. Trabajo (s) citado (s): Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV Cancer 2001 1Feb;91(3):412-20. Low -Risk in Women in Catania, Sicily. Agodi A, Barchitta M, La Rosa N, et al. Int J Gynecol Cancer 2009 Aug;19(6):1094 -8. Trabajo (s) citado (s): Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV J Cancer 2001 Solid J Transpl Dec;9(Suppl 4):S151-S160. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against population-based study . Cancer Prev curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Vaccarella S cancer in Warsaw, Poland. Bardin A, Vaccarella S, Cliffoyd GM, et al. J Cancer 2008 Mar;44(4):557-64. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Vaccarella S Onuki M, Matsumoto K, Satoh T, et al. Cancer Sci 2009 Jul;100(7):1312- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group , Lazcano-Ponce E. ). Quadrivalent Disease Development. Cancer Epidemiol Biomarkers Prev Jun;18(6):1777- 84. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine cytopathologic findings. Cathro HP, T, Dominguez F, et al. Hum Pathol 2009 Jul;40(7):942- 9. Trabajo (s) citado (s): Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV Cancer 2001 1Feb;91(3):412-20. 439) Human A Flaherty DK, Alkhateeb FM. Ann Pharmacother 2009 Apr;43(4):740- 4. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine cervical cancer from an admixtured population in Brazil. Junes-Gill K, Sichero L, Maciag PC, et al. . J Med Virol 2008 Nov;80(9):1639- 45. Trabajo of papillomavirus 16 and a case-control study. Natl NEJM 2. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine YouTube. Ache KA, Wallace LS. Am J Prev Med 2008 Oct;35(4):389- 92. Trabajo (s) citado (s): Lazcano- Ponce E. Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res 2001 May-Jun;32(3):243-7. 443) Human Papillomavirus Vaccination in the Prevention of MJ. Int J Cancer 13. Trabajo . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents J 2007 Mar;26(3):201-9. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine to vaccinate women older than 26? Skinner SR, Garland SM, Stanley MA, et al. Med J Austr 2008 18Feb;188(4):238- 42. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 445) Human papillomavirus on a therapeutic novelty. Gonzalez CA, Ascanio ADC. Atencion Primaria 2008 Apr;40(4):205- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Mar;152(3):305- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine vaccine. Kim KH. J Kor Med Assoc 2008 Feb;51(2):144- 57. Trabajo (s) citado (s): Reisinger KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents Acceptability Among Young Adult Men. Gerend MA, Barley J. Sex Transm Dis 2009 Jan;36(1):58- 62. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- KS . Block E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Garcia and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 15Mar;122(6):1311- 8. Zimet of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- Human papillomavirus vaccine A, Barretina MP. Transl Oncol 11. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine parent concordance. Breitkopf, Pearson, et al. 2367 of acceptability. 31Aug;24(Suppl 3);201- 9. Human papillomavirus reality. Smith-McCune KK. Gynecol Oncol 2008 Oct;III(1):1- 2. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine an Area with Elevated Rates of Cervical Cancer. Gottlieb SL. Brewer NT. et al. Journal of Adolescent Health 2009; 45(5): of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. Human Papillomavirus Vaccine Safety in S, Christensen Pharmacother 2009 Feb;43(2):356- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus- particle vaccine in preadolescents and adolescents al. J Womens Health 2009 Oct;18(10):1679-86. 68 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of vaccine Vaccine 31Aug;24(Suppl 3);201- Human papillomavirus Jenson HB. Pediatr 2009 Feb;21(1):112- 21. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Irala J Med 6Sep;131(7):256- 63. Trabajo Zimet of vaccine Human papillomavirus vaccine: R. et al. Pediatr 2008 Aug;20(4):441 -5 Trabajo (s) citado (s): asbach Elbasha Vaccine 2007, 26:128-139. 459) Human papillomavirus Chilean Infectious Diseases Society. September 2008. Abarca K, Valenzuela MT, Vergara R, et al. Rev Med Chile 2008 Nov;136(11):1485 -92. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Garcia and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8. Reisinger KS . Block SL E et Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 460) Human papillomavirus vaccine. Statement of VF, et al. Rev Chil Infectol 2008 Dec 25(6):428 -34. Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Reisinger KS . Block SL Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents Garcia and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against Stantey Clin Oncol Aug;20(6):388- 94. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . A, Creed P, et al. Ther 2009 Mar- Apr;22(2):150- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine view. Trollfors B. Expert Rev Vaccines 2008 Oct;7(8):1131- 3. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Garcia and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8. 464) Human KA. Sep;51(3):527- 32. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine future. Kawana K, Yasugi T, Taketani Y. Ind J Med Res 2009 Sep;130(3):341- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Bazaldua et Med Jul;120(2):79 -84. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine et al. BMC Infect Dis 2009 12Feb;9:Article 16. Trabajo (s) citado (s): Plann Reprod Health Care 2008 Jan;34(1):3- 4. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . variants Zehbe I, Richard C, DeCarlo CA, et al. Virology 2009 5Jan;383(1):69- 77. Trabajo of papillomavirus 16 and a case-control study. et al. Chin J Cancer Res of papillomavirus 16 and a case-control study. J Natl Cancer Inst 2001 1Sep;93(17):1325-30. Cancer and HPV Vaccines . Erdman JN. Am Law citado of Human Papillomavirus Vaccine Acceptability in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L73-L79. Pandey Choudhuri G, et al. Cancer 2008 15Oct;186(2):63- 8. to human papilloma viruses. Stanley MA. Ind J Med Res 2009 Sep;130(3):266- 76. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 117. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Years. Petaja T, Keranen H, Karppa T, et al. J Adolesc Health 2009 Jan;44(1):33 -40. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine aged 15-55 years. Schwarz TF, Spaczynski M, Schneider A, et al. Vaccine 2009 22Jan;27(4):581- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine in gallbladder mucosa samples with or without cancer. Roa I, Elorza X, Lantadilla S, et al. Rev Med Chile 2009 Jul;137(7):881- 7. Trabajo (s) citado (s): Lazcano- Ponce EC. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 71 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus -like particle vaccine in a sexually active populati on of North American women. Barr E, Gause CK, Bautista OM, et al. Am J Gynecol 2008 Mar;198(3): Article: 261.e1. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine in Mexican Women: Public Health Implications for th e Region. Lazcano- Ponce E, Perez G, Cruz -Valdez A, et al. Arch Med Res 2009 Aug;40(6):514 -24. Sp. Iss. SI. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Mantovani al. et al. Hum Reprod Update 2008 Jan-Feb;14(1): 59-72 Trabajo (s) citado (s): L\u00f3pez -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C. Reyes R et al (1997) dichlorodiphenyltrichloroethane serum levels and breast cancer 2000 15Aug;152(4):363- 70. 485) Implicaciones \u00e9ticas y sociales de la introducci \u00f3n de la vacuna contra el virus del papiloma humano en M\u00e9xico: reflexiones sobre una propuesta de i ntervenci\u00f3n. Prieto de la Rosa A. Guti\u00e9rrez -Delgado C. et al. Acta Bioethica 2008;14(2):157 -65. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine et al. Clin Translat poverty: Mortality differences between urban and rural areas Mexico Publica Mex cervical carcinoma in Mexico - Impact of screening, 1980- 1990. Acta Cytol 1996 May-Jun;40(3):506- 12. 488) In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Zhang R. et al. Apoptosis 2008;13:1465- 78 Trabajo (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- control J 1994;139:263- 71. 489) In vitro Hepatic and Skin Chanda S. et al. Drug Metab Disposition 2008 apr;36(4):670 -5 Trabajo (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- Incidence, mortality, and prognostic factors of small cell carcinoma Macdonald OK, Gaffney DK. Obstet Gynecol 2008 Asian-American of papillomavirus 16 and a case-control study. J Natl Cancer High-Grade Cervical Intraepithelial Neoplasia Among Smokers Experience From the Latin American Screening Study . Sarian LO, Hammes LS, Longatto A, et al. Sex Transm Dis 2009 Apr;36(4):241- 8. Trabajo (s) citado (s): MLB, Siskind DM, et al. Cancer Causes Control 2009 Nov;20(9):1571- 85. Trabajo (s) citado E . population Mexico Cancer Res 1999 1Aug;59(15):3658- Inequalities in breast and cervical cancer screening among urban Mexican women . Couture MC, Nguyen CT, Alvarado BE, et al. Prev Med 2008 Nov;47(5):471- 6. Trabajo (s) citado (s): Lazcano-Ponce EC . Najera Aguilar P . Buiatti Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The cervical cancer screening program Mexico: problems case-control M, Maldonado-Bernal Salud Publica Mex 2009 Sep-Oct;51(5):427-433. Trabajo (s) citado (s): Trejo -de la OA Epidemiologic panorama of stomach cancer mortality in Mexico. Arch Med 2001;32:312 - Infections and cancer: Established associations Crit Rev Jun;70(3):183- 94. citado infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int PE, Kreimer AR, Wacholder S, et al. J Infect Dis 2009 1Jun;199(11): 1612-20. Trabajo (s) infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int vaccines. Haynes JR. Expert Vaccines citado KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents papillomavirus vaccination: parents allow? Vallely LA, Roberts SA, Kitchener HC, et al. Vaccine 2008 24 Apr;26(18):2203-10. Trabajo (s) citado (s): Zimet GD. al. Oncol 2008 May;109(2):S4-S11. Suppl. 1. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Lemarie J Immunol 2008;180:6010-7 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of t L. et al. Toxicol 2008;23(2):263 -8 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of SG, et al. PLoS One 2009 e8237. Trabajo lactation of contamination by DDT -derivative pesticides. Zumbado M. et al. Growth Horm IGF Res 2009 Trabajo (s) citado (s): L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L 23. Trabajo (s) citado . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and vaccine acceptability. Vaccine 31Aug;24(Suppl 3);201- Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean. Franco EL, Tsu V, Herrero R, et al. Vaccine 2008 19Aug;26(Suppl 11):L88 -L95. Trabajo (s) citado (s): Murillo R . Almonte M Pereira A . Ferrer . . Cervical Screening Programs in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48. 506) Integrazione tra vaccinazione e screening di popolazione. Costa S. Formelli G. et al. Riv It Ost Gin 2008;19 Sp:920 Trabajo Zimet vaccine Vaccine 2006 31Aug;24(Suppl 3);201- the Human Antigen and HPV-16 risk of invasive cervical cancer. Souza PSD, Maciag PC, Ribeiro KB, et al. BMC Cancer 2008 22Aug;8: Artic 246. Trabajo of papillomavirus 16 and a case-control study. J Natl Cancer Inst 2001 1Sep;93(17):1325-30. non-steroidal antiinflammatory drugs, gastrointestinal damage and prevention human beings. Mozsik G. et al. Inflammopharmacol 2009 Jul;17(3):113- 50 Trabajo citado (s): L\u00f3pez-Carrillo G. Ram\u00edrez-Espitia C. et al. (s) citado (s): Sicinschi L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Dig Sci 2009; (s) citado (s): Sicinschi LA. L\u00f3pez-Carrillo L . Constanza-Camargo M. et Int. J. Cancer. 118:649 -657. 511) International curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV cytology . Int J Cancer 2001 1Feb;91(3):412-20. 512) Interpretaci\u00f3n del desempe\u00f1o operativo de las pruebas de tamizaje y de diagn\u00f3stico en enfermedades en obstetricia y ginecolog\u00eda. Gait\u00e1n_Duarte H. Rubio Ginecol remain. Paavonen J, Lehtinen M. Ann 40(3):162- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine L. et al Eur J Cancer 2009 Nov;45(16):2860 -6 Trabajo (s) citado (s): Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Cancer. Invited ready for use in cervical cancer screening? Castle PE. Am J Epidemiol 2008 15Jul;168(2):138- 44. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NCI-60 panel as model. Charasson V. et al. Eur J Cancer 2009;45:2931-2401 75 Trabajo (s) citado (s): Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D Is folic acid good for everyone? Smith AD, Kim YI, Refsum H. Am J Clin Nutr 2008 Mar;87(3):517-3 3. vaccination? Wright TC, Bosch FX. Vaccine 2008 14Mar;26(Suppl 1):A12-A15. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine variants respect to p53 degradation. Hiller T, Stubenrauch F, Iftner T. J Med Virol 2008 Mar;80(3):478- 83. of papillomavirus 16 and a case-control study. J Natl Cancer Inst A, et al. Medecine Sciences 2008 Mar;24(3):306- 13. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine on cervical cancer prevention. Alternatives for medical education. Salud Publica Mex 2000 Jan -Feb;42(1):34 -42. Lazcano- Evaluation model the Mexican national program for early cervical cancer detection and proposals for a new cervical carcinoma in Mexico - Impact of screening, 1980- 1990. Acta Cytol 1996 May-Jun;40(3):506- 12. 522) Knowledge about infection with human papillomavirus: A systematic review. Klug SJ, Hukelmann M, Blettner M. Med 2008 Feb;46(2):87- 98. Trabajo (s) citado (s): Lazcano- Ponce E. Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res 2001 May-Jun;32(3):243-7. 523) Knowledge and interest of Turkish women about cervical cancer and HPV vaccine. Baykal C, Al A, Ugur MG, et al. Eur J Gynaecol Oncol 2008;29(1):76- 9. Trabajo (s) citado (s): Lazcano- (HPV) vaccine among mothers of adolescents in Cuernavaca, . Arch Med 2001 May-Jun;32(3):243-7. Zimet GD. of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. 524) Knowledge, Attitude and Practice of screening for cervical cancer among female students of a Akujobi CN, Ikechebelu JI, I, et al. Niger J Clin Pract 2008 Sep;11(3):216- 9. Trabajo (s) citado (s): 76 Lazcano-Ponce EC. Moss among users of a cervical cancer detection center : Arch Med Res 2002 Mar-Apr;33(2):186-92. 525) Knowledge of Cervical Cancer Screening, al. J Low Genit Tract Dis 2009 Oct;13(4):200- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM et al. Int J Gynecol Cancer 2008 Sep-Oct;18(5):1020-6. Trabajo (s) citado (s): Flores Results of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. 527) La dieta y su asociaci\u00f3n con lesiones preneopl\u00e1sicas y c\u00e1ncer g\u00e1strico en una zona de alto riesgo para c\u00e1ncer g\u00e1strico en Colombia I, 2000-2006. Mart\u00ednez T. et al. Rev Colomb Cancerol 2008;12(2):74- 88 Trabajo (s) citado (s): Factors and the Risk of Gastric Cancer in Mexico City. Am J Epidemiol 1999;149(10):925- 32. 528) La inflamaci\u00f3n y su papel en el desarrollo del c\u00e1ncer g\u00e1strico. Alpizar-Alpizar W. et al. Acta Med Costarric 2009 Abr-Jun;51(2):77- 82 Trabajo (s) citado (s): Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Int. J. Cancer. 118:649 -657. 529) La mujer \u00edndigena, vulnerable a c\u00e1ncer c\u00e9rvicouterino: Pespectiva desde modelos conceptuales de salud p\u00fablica. Torres-Poveda KJ. Arredondo-L\u00f3pez AA. Duarte-G\u00f3mez MB. Madrid-Marina V. Salud en Tabasco 2008 Sep-Dic;14(3) Trabajo (s) citado (s): Palacio poverty: Mortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Supl 3):S315-S325. 530) Lack of Fertility Toxicol 2008 Dec;83(6):561- 72. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine cancer: a multisite case -control study in Uruguay. Aune D. et al. Cancer Causes Control 2009;20:1605-1615 (s): Ward Dietary Factors and the Risk Gastric Cancer in Mexico Am J Epidemiol 1999;149(10):925- 32. the State of Mexico . Cerecero P, Hernandez B, Aguirre D, et al. Salud Publica Mex 2009 Nov -Dec;51(6): 465-73. Trabajo (s) citado (s): breast cancer risk in Mexican women . Salud Publica Mex 2008 Mar- Apr;50(2):126-35. 533) (s) citado (s): Torres -S\u00e1nchez L. Galv\u00e1n -Portillo M. Wolff MS. L\u00f3pez L. (2008) Dietary consumption of phytochemicals and breast cancer 23:1-7 Linking Exposure to Polychlorinated Pregnant Women: A for Concern? Halldorsson TI. et al. Am J Epidemiol 2008 15 Oct;168(8):958- 65 Trabajo (s) citado (s): Verner in a prospective cohort of women. Larsson SC. et al. Am J Clin Nutr 2009;89(1):277 -82 Trabajo randomized study . Potena Grigioni F, Masetti M, et al. Transplantation 2008 27Apr;85(8):1146- 50. Trabajo (s) citado monovalent human papillomavirus type 16 vaccine . Rowhani-Rahbar A, Mao C, Hughes JP, et al. Vaccine 2009 18Sep;27(41):5612- 9. Trabajo (s) citado (s): P\u00e9rez G. Lazcano -Ponce E. Hern\u00e1ndez-Avila M . Garcia and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- al. Int J Gynecol Cancer 2009 (s) citado Androl 2008;31(2):233- 40 Trabajo (s) (s): L\u00f3pez -Cervantes M. -S\u00e1nchez L E. Trabajo (s) (s): et Ann Oncol 2008 Jan;19(1):168 -72. Trabajo (s) citado Int J Gynecol Cancer 2005 Sep -Oct;15(5 Major clinical advances in gynecologic 20(4): 203-209. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E.). Quadrivalent vaccine against human NEJM case cervical cancer prevention: what about equity? Tsu VD, Levin CE. Reprod Health Matt 2008 Nov;16(32):104- 12. Trabajo (s) (s): poverty: Mortality differences between urban and rural areas in Mexico Salud Publica Mex 2003;45(Suppl . Lazcano-Ponce Castro Schiavon R citado Schiavon R Serwadda D, RH. NEJM 2009 308. Trabajo (s) citado (s): Giuliano AR . Lazcano E. Villa LL detection among men the HIM study . Int Cancer 2009 Mar;124(6):1251- 7. 548) Male circumcision, human papillomavirus evidence to FX, Albero G, Castellsague X. J Fam Plann Reprod Health Care 2009 Jan;35(1):5- 7. Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R Mexico J Cancer of citado curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 550) Managing cancer risk and decision kidney transplantation. Webster AC, Wong G, Craig JC, et al. Am J Transpl 2008 Nov;8(11):2185- 91. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Health and Medical Professionalism. Rothman SM, Rothman DJ. JAMA 2009 19Aug;302(7):781- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Buttery Madin NW, et al. Med J Austr 2008 1Sep;189(5):261- 2. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine AY. et al. Toxicol Sci 2009;112(1):144- 52 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et Assessm ent of lymphocyte and cytokine to arsenic. 20(6):779 -781. 554) Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean . Goldie SJ. et aL. Vaccine 2008 Aug;26(Suppl 11):L59 -L72 Trabajo (s) citado (s): A. Desreux J. Berrino F. Boutron MC. Romieu I. Clavel F. et al. Progestagens use before menopause Ferris JL, Miller J, et al. J Low Genit Tract Dis 2008 Oct;12(4):276- 81. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Boccia S. et al. Am J Epidemiol 2009 Trabajo (s) citado (s): Lacasa\u00f1a-Navarro M. Galv\u00e1n-Portillo 2006;42:528- 533. 558) Meta-analysis of intrauterine device use of endometrial cancer . Beining RM, Dennis LK, Smith EM, et al. Ann Epidemiol 2008 Jun;18(6):492- 9. Trabajo (s) citado (s): . population L. et al. Eur J Prev -52 Trabajo (s) citado(s): Boccia S. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D Disorders. Maes OC. et al. Curr Genomics 2009 May:10(3):154 -68 Trabajo (s) citado (s): Ruiz -Ramos R. L\u00f3pez -Carrillo L. Rios -P\u00e9rez -Ru\u00edz ME. Sodium arsenite induces ROS Mar and of knowledge hinder cervical cancer prevention. Moodley J, Harries J, Barone M. South Afr Med J 1999 Mar;99(3):128. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Cooke CL, Kim J, et al. Gastroenterology 2009 Sep;137(3):1 061-71. in the development of cervical cancer . Gutierrez -Xicotenc atl L, Plett -Torres T, Madrid CL, et al. Salud Publica Mex 2009;51(Suppl 3):S479 -S488. Trabajo (s) citado (s): Flores Y . Lazcano screening strategy in Mexico: The Morelos HPV . Salud Publica Mex 2002 Jul-Aug. 44(4):335- 44. Ponce need for . Salud Publica Mex 2003;45(Suppl Ponce Herrero R . Munoz N Cruz A . Shah KV . Int J Cancer 2001 1Feb;91(3):412-20. 564) human papillomavirus. Hoory T, Monie A, Gravitt al. J Assoc Mar;107(3):198 -217. Trabajo (s) citado curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Salmeron . Uribe M . Manzanares H . Antunez A. State, Mexico . Cancer Causes Control 2003 Aug;14(6):505-12. 565) Molecular pathogenesis neck cancers. Singh B. J Surg Oncol 2008 15Jun;97(8):634- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine al. Nat Rev Drug Discov 2009 Mar;8(3):213- 25. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Villa LL. Vaccine 2008 14Mar;26(Suppl 1):A24 -A27. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine al. J Adoles Health 2009 May;44(5):446- 51. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Themselves to Receive the Human Papillomavirus Vaccine: A National Study of Nurses. Kahn JA, Ding LL, Huang B, et al. Pediatrics 2009 Jun;123(6):1439 -45. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 31Aug;24(Suppl Alcohol Exp Res 2009 -7 Trabajo (s) Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. JY. CM. T. F. Lacasa\u00f1a -Navarro D in Chinese women. Gao CM. Tang JH. et al. J Human Genet 2009; 54(7): 414- 418. Trabajo (s) citado (s): Boccia S. R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D M. et al. Genet 2009 Oct;47(9-10):645- Trabajo (s) citado (s): Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D in and determinants. Wentzensen N, Schiffman Dunn T, et al. Int J Cancer 2009 1Nov;125(9):2151- 8. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. al. Cancer Prev . Lazcano-Ponce Castro Schiavon R factor for cervical carcinogenesis in older women. Cui B, Zheng B, Zhang X, et al. Int J Oncol 2009 Feb;34(2):409- 16. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 576) Mycotoxines : L. L\u00f3pez -Carrillo L. Peng JH. Sutcliffe AE. White KL. Humpf HU. Turner PC. Wild CP. (2008) Association between tortilla cons umption and human urinary biopsy specimens. Roa I, Munoz S, Ibacache G, et al. Rev Med Chile 2009 Jul;137(7):873 -80. Trabajo (s) citado (s): Lazcano- Ponce EC. Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine. Garland SM, Steben M, Sings HL, et al. J Infect Dis 2009 15Mar;199(6):805- 14. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Dec;35(4):519+. 82 Trabajo (s) citado (s): Franceschi S curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 580) Negative association between plasma levels of adiponectin and polychlorinated biphenyl 153 in under non -energy -restrictive regi me. Mullerova D. et al. Int J Obes 2008;32:1875 -8 Trabajo (s) citado (s): Verner novel screening strategies Syrjanen K. Eur citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Vaccare lla S. Munoz N . Cruz A . Shah KV Cancer 2001 1Feb;91(3):412-20. 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine X, Carreras R. Med Clin 2008 7Jun;131(1):30 -4. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine acute otitis parents be willing to have their children immunized? Dube E. de WalsP. et al. Int of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl al. Biol 2008 Mar;27(3):127- 32. Trabajo (s) citado Nobel price for vaccination against cervical cancer: Current data and guidelines. Hepburn HM, Kaufmann AM. Internist 2009 May;50(5):617- 26. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and Edefonti V, Decarli A, C, et al. Int J Cancer 2008 1Feb;122(3):609 -13. 83 Trabajo (s) citado . Cancer 2002;43(2):133- 40 590) Obtenci\u00f3n de biopsia con laringoscopio flexible y canal de trabajo como m\u00e9todo diagn\u00f3stico de c\u00e1ncer de laringe. Ponce-Belloc MB. et al. An Orl Mx 2009;54(2):67- 70 citado (s): Tovar-Guzman VJ. Barquera S. L\u00f3pez-Antu\u00f1ano FJ . Tendencias de mortalidad por c\u00e1nceres atribuibles a tabaco en M\u00e9xico. Salud Publica Mex 2002;44:20- 24 591) One -carbon metabolism and breast cancer: J. J Genom 2009 Apr;36(4):204 -14 Trabajo (s) citado (s): Lajous M. Romieu I. Sabia S. and postmenopausal prospective of French women. Cancer Causes Control 17, 1209 -1213, 2006. and secondary cervical era cervical vaccination: A multi-regional health economic analysis. Rogoza RM, Ferko N, Bentley J, et al. Vaccine 2008 15Sep;26(Suppl 5):F46-F58. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine al. Int J Gynecol Obstet 2008 Feb;100(2):175- 8. Trabajo (s) citado (s): Al-Saleh et Sci Monit 2009 Nov;15(11):BR320-BR333. Trabajo citado (s): HPV Vaccines in Low-Income Countries. Tsu VD. Am J Law Med 2009;35(2-3):401- 13. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine KS . Block E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . Pediatr Infect Dis J 2007 Mar;26(3):201-9. 596) Panorama epidemiol\u00f3gico de la mortalidad por c\u00e1ncer cervicouterino en M\u00e9xico (1980 -2004). Tovar -Guzm\u00e1n VJ. Ortiz -Contreras F. et al. Rev Fac Med UNAM 2008 Mar -Abr;51(2):47 -51. Traba jo(s) citado (s): poverty: Mortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Supl 3):S315-S325. Y, Nguyen TT, et Health 2009;14(6):575- 89. Trabajo (s) citado (s): Lazcano- Ponce EC. Castro R . Allen B . P . De Ruiz of J Womens Apr;8(3):399- 408. 598) Papilloma Virus Vaccine Reply. Gonzalez CA, Ascanio AD. Atencion Primaria 2008 Nov;40(11):585- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine the External Ear Canal: Report of Ten cases in Chinese Patients with HPV In Situ Hybridization. Wang S. Yee H. et al. Head and Neck Pathol 2009 Sep;3(3):207 -211 Trabajo Block Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents Vaccine Availability: Uptake and Intentions. Gerend of Adolescent of vaccine acceptability. Vaccine Istrate C, Hinkula J, Charpilienne A, et al. Vaccine 2008 18Aug;26(35):4594- 601. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Indian -70 Trabajo (s) citado Torres R. Ochoa-Fierro Mexican pilot study. Int Arch Occup More Supportive of the Human Papillomavirus Vaccine than the General Public. Ishibashi KL, Koopmans J, Curlin FA, et al. South Med J 2008 Dec;101(12):1216- 21. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine et al. J Adolesc Health 2008 Oct;43(4):408- 11. Trabajo (s) citado (s): Zimet -50. Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R DG. 90 citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: case- transmission of human papilomavirus DNA. RL. Serafini EP. et al. pregnant women Morelos, 2005 citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- Immunol Dec;22(6):445- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine M. et al. 2008 29Sep;251(1-3):51- 60 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian et Assessment of lymphocyte subpopulations cytoki ne Hung R. Ricci ardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. T. F. Lacasa\u00f1a -Navarro D . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents J 2007 Mar;26(3):201-9. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 77. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against Causes Control 2009 Sep;20(7):1107- 15. Trabajo Hernandez-Avila M .Case-control physical . and endometrial Health Study . Gierach GL, Chang SC, Brinton LA, et al. Int J Cancer 2009 1May;124(9):2139- 47. Trabajo (s) citado (s): Salazar E. Lazcano-Ponce E Hernandez-Avila M .Case-control physical Causes Control Hernandez-Avila M .Case-control physical al. Environ Health Perspect 2008 92. -S\u00e1nchez et al. Eur J Cancer Prev 2009 Feb;18(1):13 -25 Trabajo (s) citado (s): L\u00f3pez-Carrillo L. Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case- control study. 1994;139:263- 71. 620) Pitfalls in the epidemiologic classification types associated chain reaction: Cancer Oct;18(5):1042-50. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . Scand 2009;88(4):457 2002;63(2):151-7. 622) Plasma folate, vitamin B -6, vitamin B -12, and risk of breast cancer in women. Lin J. et al. Am J Clin Nutr 2008 Mar;87(3):734 -743 Trabajo (s) citado and postmenopausal prospective of women. Control 17, 1209 A nested case - control study. Iwasaki M. et al. Sci Tot Environ 2008 1Sep;402(2 -3):176 -83 Trabajo (s) citado (s): L\u00f3pez -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C. Reyes R et a l (1997) dichlorodiphenyltrichloroethane serum levels and breast cancer L\u00f3pez 15Aug;152(4):363- 70. 624) vitamin B12 concentrations and risk of colorectal cancer: A nested case-referent study. Dahlin AM. et al. Int J Cancer 2008 1May;122(9):2057-2061 87 Trabajo (s) citado (s): Lajous M. Romieu I. Sabia S. and postmenopausal prospective of French women. Cancer Causes Control 17, 1209 -1213, 2006. 625) Pobreza y marginalidad como criterio de priorizaci\u00f3n para las enfermedades catastr\u00f3ficas en M\u00e9xico. Santos- Padr\u00f3n H. Rev C ub Salud p\u00fablica 2008;34(2) Trabajo (s) citado (s): Palacio poverty: Mortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325. 626) low-resource settings. Tsui J. LaMontagne DS. et al. The Open Vaccine Journal 2009;2:113- 22 Trabajo (s) citado (s): Zimet GD. vaccine Vaccine 2006 31Aug;24(Suppl 3);201- 9. pediatric acute lymphoblastic leukemia. Jonge R. et al. citado (s): Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D Trabajo (s) citado (s): L\u00f3pez -Carrillo L. L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L. Blair A. Cebri\u00e1n -Garc\u00eda M. Garc\u00eda RM. (2002). Serum levels and polychlorinated 629) Population-based prevalence, of HPV program in Denmark. Kjaer SK, Breugelmans Munk C, et al. Int J Cancer 2008 15Oct;123(8):1864- 70. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 630) Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Newall AT, Brotherton JML, Quinn HE, et al. Clin Infect Dis 2008 1Jun;46(11):1647- 55. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and ;170(10):1257 -1267 Trabajo (s) citado and postmenopausal prospective of French women. Causes Control 17, 1209 2006. HPV Vaccine Provision Among Medical Practices in an Area with High Rates of Cervical Cancer. Keating KM. Brewer NT. et al. J Adolesc Health 43(4): related cancer of the penis and vulva in Jamaica. Fletcher HM, Hanchard B. J Obstet Gynaecol 2008 Apr;28(3):333- 5. Trabajo (s) citado (s): 88 curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 634) Practical relevant (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Cancer Prevention Programs in the United States. Castle PE, Solomon D, Saslow D, et al. Cancer 2008 15Nov;113(10):3031-5. Suppl. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Clinical Trials of a Human Papillomavirus Type Vaccine A Analysis of Five Randomized Controlled Trials. Garland SM, Ault Gall SA, et al. Obstet Gynecol 2009 Dec;114(6): 1179- 88. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and DY, et al. Int J Cancer 2009 Jan;19(1):147- 51. Trabajo (s) citado (s): . population Cancer Res 1999 1Aug;59(15):3658- . Scand 2009;88(4):434 -9. Cancer . Harries J, Moodley J, Barone MA, et al. Vaccine 2009 1Jan;27(1):38- 44. Trabajo (s) citado (s): Lazcano-Ponce EC. Moss S de MH cancer screening in developing countries: Why is it ineffective? The case of Mexico . Arch Med Res 1999 May-Jun;30(3):240-50. Zimet GD. vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. 640) Prevaccination Distribution of Human Papillomavirus Types in Women Attending at Cervical Cancer Screening in Belgium. Arbyn Prev Jan;18(1):321- 30. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 641) Prevalence and Age Distribution of Human Papillomavirus Infection in a Population of Inuit Women in Nunavik, Quebec. Hamlin-Douglas LK, 2008 Nov;17(11):3141- 9. Trabajo (s) Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV Cancer 2001 infection a rural Uganda. Asiimwe S, Whalen CC, Tisch DJ, et al. Int J STD AIDS 2008 Sep;19(9):605- 10. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Workers Differences by Geographical Origin. del Amo J, Gonzalez C, Belda J, et al. J Womens Health 2009 Dec;18(12):2057-64. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 644) Prevalence, Acquisition, and Clearance with Normal Goodman MT, Shvetsov YB, McDuffie K, et al. Cancer Res 2008 1Nov;68(21):8813- 24. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV Cancer 20 01 C, Franceschi S, van Doorn LJ, et al. Int J Cancer 2008 1Nov;123(9):2180- 7. Trabajo (s) citado (s): 2005 Oct;32(10):613-8. for anal human papillomavirus infection in heterosexual men. Nyitray A, Nielson CM, Harris RB, et al. J Infect Dis 2008 15Jun;197(12):1676- 84. Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R Sypsa D, et al. J Med Virol 2009 Dec;81(12):2059 -65. Trabajo (s) citado infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int squamous cell abnormalities and associated factors in women of a rural town of Colombi a. Grisales H, Vanegas AP, Gaviria AM, et al. Biomedica 2008 Jun;28(2):271 -83. Trabajo (s) citado (s): Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV 2001 1Feb;91(3):412-20. Flores Results Morelos HPV Study . Salud Derchain SFM, et al. Rev Saude Publica 2008 Feb;42(1):123- 30. Trabajo (s) citado (s): Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV Cancer 2001 1Feb;91(3):412-20. Gynecol Nov;112(5):979- 89. Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Vaccarella S infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int J 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.Gupta S, Sodhani P, Sharma A, et al. Cytopathology 2009 Aug;20(4):249- 55. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV gy. Rifo P, et al. Rev Med Chile 2008 Nov;136(11):1381- 9. Trabajo (s) citado (s): Aguilar LV . Lazcano-Ponce Vaccarella papillomavirus genotypes in women fro m a rural region of Puebla, Mexico. Velazquez - Marquez N, Paredes -Tello MA, Perez -Terron H, et al. Int J Infect Dis 2009 Nov;13(6):690 -5. Trabajo (s) citado (s): Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV cytology . J Cancer 2001 1Feb;91(3):412-20. Hern\u00e1ndez Campos Mexico: case-control study . Arch Med Res 199 7 Summer;28(2):265- 71. 655) Prevalence of human papillomavirus in Indonesia: a population -based study in three regions. Vet JNI, de Boer MA, van den Akker BEWM, et al. Br J Cancer 2008 8Jul;99(1):214 -8. Trabajo (s) citado (s): 91 Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Vaccarella S Munoz N . Cruz A . Shah KV Cancer 2001 1Feb;91(3):412-20. human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial. Six L, Leodolter S, Sings HL, et al. Wiener Klinische Wochenschrift 2008 Nov;120(21-22):666- 71. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and 2007 Mar;26(3):201-9. Prevalence papillomavirus type 16 and its in squamous in Northeast Thailand. Chopjitt Ekalaksananan T, Pientong C, et al. Int J Infect Dis 2009 Mar;13(2):212- 9. Trabajo (s) citado of papillomavirus 16 and a case-control study. Natl of papillomavirus 16 and a case-control study. Natl Cancer -Talonen A, et al. Int J Cancer 2008 15Sep;123(6):1344 -9. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 660) Prevalence of Single and Multiple Human Papillomavirus Types in Cervical Cancer and Precursor Lesions in Hubei, . Cai HB, Ding XH, de MH cancer screening in developing countries: Why is it ineffective? The case of Mexico . Arch Med Res 1999 May-Jun;30(3):240-50. 661) Prevalence of type-specific HPV infection by age and of cytology: data from the ARTISTIC trial. Sargent A, Bailey A, Almonte M, et al. Br J Cancer 2008 13May;98(10):1704- 9. Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 662) Preventing Cancer. Molokhia EA, Perkins A. Primary Care 2008 Dec;35(4):609. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine the HPV vaccine. Waxman AG, Zsemlye MM. Med Clin North Am 2008 Sep;92(5):1059. 92 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Med May;163(5):487- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 2009 21Feb;122(2):126- 7. Trabajo (s) citado (s): Villa LL, et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and Associated Diseases by Vaccination: A New Hope for Global Public Health. Harper DM. Public Health Genom 2009;12(5-6):319- 30. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 1Apr;101(7):439 -40. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Expert Mol Diagn 2009 Nov;9(8):851- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine al. Am J Health Syst Pharm 2009 1Feb;66(3):237- 57. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 62(4):338 -342 (s) citado (s): S.Gompel A. Desreux J. Berrino F. Boutron MC. Romieu I. Clavel F. et al. Progestagens use before menopause M, Nakagawara H, et al. Ann Surg 2008 Nov;248(5):807 -14. Trabajo (s) citado (s): Lazcano- Ponce et al. Mol Carcinogen 2009 Jan;48 (1):79- 89. Trabajo (s) citado (s): Lazcano- the convention on tobacco control: A case study of challenges and opportunities for strategic communications in Mexico. Thrasher JF. et al. Evaluat Health Prof 2008 Jun;31(2):145- from lung cancer in Mexico, 1980 -2000. Revista Panamericana Salud P\u00fablica , 17(4),254 -262. 675) Prophylactic HPV vaccination for women over 18 years of age. Adams M, Jasani B, Fiander A. Vaccine 2009 26May;27(25-26):3391-4.Sp. Iss. SI. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine breakthrough in the fight against cervical cancer? Saleem A, Tristram A, Fiander A, et al. Minerva Medica 2009 Dec;100(6):503 -23. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine The Open Access Vaccine Journal 2009;2:123- 33 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and E, Sings HL. Vaccine 2008 18Nov;26(49):6244 -57. Sp. Iss. SI. Trabajo (s) citado (s): Franceschi S . Herrero R age-specific curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine .. J Infect Dis . Block SL Lazcano-Ponce E et Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and of human papillomavirus vaccines in India. Das BC, Hussain S, Nasare V, et al. Vaccine 2008 23May;26(22):2669- 79. Trabajo (s) citado (s): Franceschi S curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 680) Pruebas moleculares para la detecci\u00f3n del virus papiloma humano. Desaf\u00edos y posibilidades. Cavazza ME. Correnti M. Dermatolog\u00eda Venezolana 2004;42(3):6- 10. Trabajo (s) citado (s): Dzuba IG. Yunes -D\u00edaz E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acceptability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & Gende r-Based Sep-Oct;15(5):384- 92. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Papilloma Virus (HPV) vaccination. Walsh CD. Gera A. et al. BMC Public 2008;8. Trabajo (s) (s): 94 Zimet Vaccine 31Aug;24(Suppl Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The cervical cancer screening program Mexico: problems breast cancer risk in Mexican women . Salud Publica Mex 2008 Mar- Apr;50(2):126- 35. L\u00f3pez -Rios . Lazcano-Ponce lactation Epidemiol 1996 684) p53 and gallbladder carcinoma. Roa I, Lantadilla S, Ibacache G, et al. Rev Med Chile 2009 Aug;137(8):1017- 22. Trabajo (s) citado (s): Lazcano- Ponce EC. Oct;111(1):120 -4. Trabajo (s) citado (s): Lazcano- EC. de PA Mexico . Acta Cytol 1997 Mar-Apr;41(2):277- 84. Lazcano- Ponce EC. de Ruiz P A. Mart\u00ednez Arias C . Murguia Riechers L . Reproducibility study of cervical and HPV infection and related disease in women 24 to 45 years of age. Munoz N, Manalastas R, Pitisuttithum P, et al.. Ann Intern Med 2009 20Oct;151(8):JC4- 12. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Related Beliefs Among Rural, Southern Women. Cates J. Brewer NT. et al. J Rural Health 2009; 25(1): 93- 97. Trabajo (s) citado (s): Zimet Rosenthal of vaccine Vaccine 2006 31Aug;24(Suppl 3);201- Survival Head Results Res 2009 Sep;2(9):776- 81. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine al. Dec;85(7):499- 502. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine -blind randomized cli nical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Herrero R, Hildesheim A, Rodriguez AC, et al. Vaccine 2008 2Sep;26(37):4795 -808. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 690) Reassessing the epidemiology of huma n papillomavirus infection: Back to basics. Franco EL, Trottier H. Sex Transm Dis 2008 Mar;35(3):283 -5. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 691) Recent DM, Kast WM. Int J Cancer 2008 15Jan;122(2):247- 59. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Bertuccio Chatenoud L, Levi F, et al. Int J Cancer 2009 1Aug;125(3):666- 673. Trabajo (s) citado (s): the Risk Gastric Cancer in Mexico City. Am J Epidemiol 1999;149(10):925- 32. 693) Recommendations for Cervical Cancer Prevention in Asia Pacific. Garland SM, Cuzick J, Domingo EJ, et al. Vaccine 2008 19Aug;26(Suppl 12):M89-M98. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 694) Recommendations for Cervical Cancer Prevention in Latin Ame rica and the Caribbean . Munoz N, Franco EL, Herrero R, et al. Vaccine 2008 19Aug;26(Suppl 11):L96 -L107. Trabajo (s) citado (s): Murillo R . Almonte M Pereira A . . E. Cervical Screening Programs in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48. Herrero R Jeronimo J . New Approaches to Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 19Aug;26(Suppl Determinants of Human Papillomavirus Vaccine Acceptability in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L73-L79. Franco EL . Tsu V . Herrero R . Lazcano- Ponce E. Hildesheim A. Vaccination and Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95. 695) 47. Trabajo KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . Pediatr Infect Dis J 2007 Mar;26(3):201-9. 96 697) Recurrencia de c\u00e1ncer de mama en mujeres del Noroeste de M\u00e9xico. P\u00e9rez-Michel LM. Et al. Cir Cir 2009 May- Jun;77(3):179- 85 citado (s): L\u00f3pez-Carrillo L . Torres-S\u00e1nchez L . L\u00f3pez-Cervantes M. et al. Identificaci\u00f3n de lesiones mamarias en M\u00e9xico. Salud P\u00fablica de M\u00e9xico 2001;43(3):199 -202. 698) Recursos disponibles para el tratamiento del c\u00e1ncer de mama en M\u00e9xico. Mohar A. et al. Salud Publica Mex 2009;51(supl 2):S263-S269. Trabajo (s) citado (s): et Biochem 2009;107(3):537- 47 Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation. Insinga RP, Dasbach EJ, Allen SE, et al. Value in Health 2008 Dec;11(7)L:1022- 32. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Among Fertile Women from of Glyphosate . Sanin LH, Carrasquilla G, Solomon KR, et al. J Toxicol Environ Health Part- A 2009;72(!5-16):949- 60. Smoking and Human Papilloma Virus Types 16 and 18 DNA Load . Xi LF, Koutsky LA, Castle PE, Biomarkers Dec;18(12):3490-6 infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int J Epidemiol 2008 Jun;37(3):536- love and sexuality: what the Filipino teens think and feel . de Irala J, Osorio A, del Burgo CL, et al. BMC Public Health 2009 5Aug;9: Artic 282. Trabajo (s) citado findings in Latin Ametica and the World. Torres -Mej\u00eda J. \u00c1ngeles -Llerenas A. Salud Publica Mex 2009;51(Supl 2):S165 Trabajo (s) citado (s): L\u00f3pez-Carrillo Ortega Altamirano D., Reproductive determinants of breast cancer in Mexican women. Ann N Acad Sci Tovar . Publica lactation J Epidemiol 1996 15Mar;143(6):543-52. 705) Reprodutibilidade do teste captura h\u00edbrida de segunda gera\u00e7\u00e3o na detec\u00e7\u00e3o de HPV de alto risco em material cervicovaginal de autocoleta. Cremonesi A. Taromaru E. et al. J Bras Doen\u00e7as Sex Transm 2004;16(4):5- 10, 2004. Trabajo (s) citado (s): 97 Dzuba IG. Yunes -D\u00edaz E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Accep tability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & Gender -Based Medicine, 2002;11(3):265 -275. Immigrant Women. KJ, Allen RH, Nothnagle M, et al. Obstet Gynecol 2009 Nov;114(5):1135- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine br\u00f3coli (Brassica Oleracea) determinados por cromatograf\u00eda de gases. P\u00e9rez MA. Et al. Rev Int Contam Ambient 2009;25(2):103- 10 Trabajo (s) citado (s): L\u00f3pez -Carrillo L. L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L. Blair A. Cebri\u00e1n -Garc\u00eda M. Garc\u00eda RM. (2002). Serum levels of and polychlorinat ed cancer Eur. Cancer Prev. 11, -135. 708) Results with screening test . al. J Inst . Uribe M . Manzanares H . Antunez A. Mexico . Cancer Causes Control 2003 Aug;14(6):505-12. 709) Chokshi DA, Kesselheim AS. BMJ 2008 5Apr;336(7647):750- 3. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Suppression through TLR Agonist Treatment of to Human Papillomavirus Type 16. Fahey LM, Raff AB, Da Silva DM, et al. J Immunol 2009 1Mar;182(5):2919- 28. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine MTHFR citado (s): Boccia S. R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D Epidemiological and biological Et World J Gastroenterol 2009 May;15(18):2204-2213 Trabajo (s) citado (s): Ward MH. Dietary Factors and the Risk Gastric in Mexico Am J Epidemiol 713) Review of Rev 2008 Mar;11(3 -4):276 (s) citado (s): L\u00f3pez -Carrillo L. L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L. Blair A. Cebri\u00e1n -Garc\u00eda M. Garc\u00eda RM. (2002). Serum levels and polychlorinated J. Prev. 11, -135. L\u00f3pez -Cervantes M. Risk Assessment Guide the Prevention of Cervical Cancer. Castle PE. Sideri M. et al. Journal of Lower Genital Tract Disease 2008; 12(1): 1- 7. Trabajo (s) citado (s): 98 Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 of prevention programmes for cervical cancer. Katki HA, Wacholder S, Solomon D, et al. Lancet Oncol 2009 Nov;10(11):1022- 3. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine HPV DNA of high types in paraepidermal epithelium cells of the uterine cervix, in the in the peripheral blood of pregnant patients . Agata T, Malgorzata S, Daria R, et al. Ginekol Pol 2008 Dec;79(12):871 -6. Trabajo (s) pregnant women Morelos, Mexico . Salud Publica Mex 2005 Nov- Dec;47(6):423-9. 717) Risk factors associated with genital M, Rodriguez -Lundes O, de Oca MELM, et al. Cir Cir 2009 Nov - Dec;77(6):419 -21. Trabajo (s) citado (s): Lazcano- Ponce EC. Hern\u00e1ndez -Avila M. L\u00f3pez -Carrillo L. De Ru\u00edz PA. Torres -Lobat\u00f3n A. Gonz\u00e1lez -Lira A. Romieu I. factors and sex life -history and c ervical -cancer in Mexico City. Rev Invest Clin 1995 Sep - Oct;47(5):377 -85. 718) Risk factors for cervical cancer women in Mexico . Flores YN, Bishai DM, Shah KV, et al. Salud Publica Mex 2008 Jan-Feb;50(1):49- 58. Trabajo (s) citado (s): Salmeron . Uribe M . Manzanares H . Antunez A. State, Mexico . Cancer Causes Control 2003 Aug;14(6):505-12. Br 2009 . population in Mexico . Cancer Res 1999 1Aug;59(15):3658- 62. 720) Risk facto rs for Human Papillomavirus Exposure and Co -factors for Cervical Cancer in Latin America and the Caribbean. Almonte M, Albero G, Molano M, et al. Vaccine 2008 19Aug;26(Suppl Trabajo (s) citado (s): Schiavon R and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8. Herrero R E. Jeronimo J. New Approaches to Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58. Murillo R . Almonte M A E . Gamboa . Jeronimo J. Lazcano-Ponce E. Cervical Cancer Screening Programs in Latin America and the Caribbean . 2008 19Aug;26(Suppl 11):L37-L48. Vaccarella of papillomavirus 16 and a case-control study. J Natl Cancer Inst Munoz N . Cruz A . Shah KV Cancer 2001 1Feb;91(3):412-20. G, et al. Mol Genet Metab 2008 May;94(1):83- 9. Trabajo (s) citado (s): Lazcano- Ponce and gene profiling in head and neck cancers. Gold KA, Kim ES. Curr Opin Oncol 2009 May;21(3):206- 11. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM Tyring Dermatol Ther (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Kang S, Kim KH, Kim YT, et al. Int J Gynecol Cancer 2008 Sep- Oct;18(5):1013- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 725) Safety and immunogenicity B (HBV) vaccines. Wheeler CM, Bautista OM, Tomassini JE, et al. Vaccine 2008 30Jan;26(5):686-96. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like- particle vaccine in Latin American women. Perez G, Lazcano -Ponce E, Hernandez -Avila M, et al. Int J Cancer 2008 15Mar;122(6):1311 -8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) r ecombinant vaccine in women aged 24 -45 years: a randomised, double -blind trial. Munoz N, Manalastas R, Pitisuttithum P, et al. Lancet 2009 6Jun;373(9679):1949 -57. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine human papillomavirus (HPV) vaccines: A review of the international ex perience so far. Agorastos T. Chatzigeorgiou K. et al. Vaccine 2009; 27(52): 7270 -7281. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Cervical Weinstein LC, Buchanan EM, Hillson C, et al. Primary Care 2009 Sep;36(3).559 100 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against 2007 10May;356(19):1915-27. primary and neck tumor risk in with cervical data analysis Ragin Sci 66. citado and postmenopausal prospective of French women. Cancer Causes Control 17, 1209 -1213, 2006. 732) Self-report is a valid measure of circumcision status in homosexual men . Templeton DJ, Mao L, Prestage GP, et al. Sex Transm Infec 2008 1Jun;84(3):187- 8. al. Gynecol Oncol 2009 Dec;115(3):S7-S14. Suppl. 1. in a community setting: Feasibility in Hispanic women. De Alba I. Anton E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acceptability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & Gender -Based Medicine, 2002;11(3):265 -275. 735) Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. al. J Infect Dis 2009 1Oct;200(7):1059- 67. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine M papillomavirus infection papillomavirus prevalence and type distribution among men residing in Brazil, and the United Cancer Epidemiol Biomarkers pes in the German general population. Michael KM, T, Sehr P, et PLoS Pathogens 2008 Jun;4(6):e1000091 Trabajo (s) citado (s): Lazcano- Ponce Herrero R . Munoz N . Cruz A . Shah KV 2001 1Feb;91(3):412-20. Japanese study. Itoh H. et al. Cancer Causes Control 2009;20:567- 80 Trabajo (s) citado (s): L\u00f3pez -Carrillo L. L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L. Blair A. Cebri\u00e1n -Garc\u00eda M. Garc\u00eda RM. (2002). Serum levels and polychlorinated J. Cancer Prev. 11, 129 -135. 101 L\u00f3pez -Cervantes M. Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C. Reyes R et al (1997) dichlorodiphenyltrichloroethane serum levels and breast cance r 70. differences in injection site reactions with human vaccines. Cook IF. Hum Vaccines 2009 Jul;5(7):441- 9. Trabajo (s) citado (s): Reisinger KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . Pediatr 2007 Mar;26(3):201-9. 739) Sexual Behaviour and HPV Infections in 18 to 29 Year Old Women in the Pre-Vaccine Era in the Netherlands . Lenselink CH, WGV, Feb;35(1):33. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine HPV. Morrison EAB. Infect Med 2009 Jan;26(1):13- 17. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM Vaccine 2009 23Jul;27(34):45 51-9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine S, Pandey SN, et Int 2009 Jul;29(6):831- 7. Trabajo (s) citado (s): Lazcano- Ponce EC. Indian Population. Srivastava Srivastava et al. 2009 Jun;16(6):1695 -1703. and human papillomavirus infection: the pursuit of credibility for an epidemiologic association (Commentary). Franco EL, Spence AR. Int J Epidemiol 2008 Jun;37(3):547-8. Trabajo (s) citado (s): Vaccarella infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int J Epidemiol infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. of cervical in Argentina . Arrossi S, Ramos S, Paolino M, et al. Reprod Health Matt 2008 Nov;16(32):50- 8. Trabajo (s) citado (s): Lazcano-Ponce EC. Moss among users of a cervical cancer detection center : Arch Med Res 2002 Mar-Apr;33(2):186-92. Herrero R . Ferreccio C Jeronimo J . New Approaches to Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58. Lazcano-Ponce EC . Najera . Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The cervical cancer screening program Mexico: problems of Human Papillomavirus Vaccine in Low-Resource Settings. Bingham AJ. Arch Pediat of vaccine Brazil. Carnei ro- Almeida L. Tomita LY. et al. Cad. Sau de P\u00fablica, Rio de Janeiro 2008 mar;24(3):587 -596, Trabajo (s) LAV, Waller J, Wardle J. J Med Screen 2008;15(2):91- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J 2006 1Dec;119(11):2677-2684. Lajous between salt consumption and helicobacter pylori infection. Wang X. et al. Asia Pac J Clin Nutr 2008;17(4):644 -50 Trabajo (s) citado (s): Ward Dietary Factors and the Risk Gastric Cancer in Mexico City. Am J Epidemiol 1999;149(10):925- 754) Study Comparing Human Assays. al. J Clin Microbiol 2009 Jul;47(7):2106- 13. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine et al. Chemother 2008 Apr;52(4):1374- 81. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 2009 Sep;1 23(3):310 -22. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine cancer: a systematic review of epidemiological studies . van der Rhee H, Coebergh JW, de Vries E. Eur J Cancer Prev 2009 26Aug. Trabajo (s) Int J Gynecol Cancer 2005 Sep -Oct;15(5 ):938 -45. 758) Sunlight, the cancer . Int J Gynecol Cancer 2005 Sep -Oct;15(5 ):938 -45. 759) Surgical management for carcinoma of the gallbladder: a single- institution experience in 25 years. Liang JW, Dong SX, Zhou ZX, et al. Chin Med J 2008 5Oct;121(19):1900- 5. Trabajo (s) citado (s): Lazcano- Ponce EC. Ponce EC. class II loci cytokine gene polymorphisms on the risk in Japanese patients with Helicobacter pylori infection. Ando T. et al. Int Cancer Trabajo (s) citado (s): Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk Cancer. 118:649 -657. 762) Systematic Gastric Risk. Gianfagna F. et al. Curr Genomics 2008 Sep;9(6):361 -74 Trabajo (s) citado (s): Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert JY. CM. T. F. Lacasa\u00f1a -Navarro D 2008 May;24(3):372- 6. Trabajo Ponce EC. JF Pharmacol Toxicol 2009;49:73- 96. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine HPV in situ. Ivansson EL, Gustavsson IM, Wilander E, et al. Int J Cancer 2009 15Dec;125(12):2930 -5. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine for detecting and LSIL) in patients affiliated to the security system in Bogota, Colombia. Isaza -Ruget MA. Perez G. Morales -Reyes 2009; -222. Trabajo (s) Murillo R . Almonte M Pereira A . . E. Cervical Screening Programs in Latin America and the Caribbean . 2008 11):L37-L48. 767) Oral Cavity . Ventura M, Turroni F, Zomer A, et al. Genet 2009 Dec;5(12):Article for a gender-neutral (Universal) human papillomavirus vaccination policy in the Cancer Epidemiol Biomarkers Prev Apr;17(4):805- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents Munoz 769) The Challenge of Eliminating Cervical Cancer in the United States: A Story of Politics, Prudishness, and Prevention. Fisher JW, Brundage SI. Women Health 2009;49(2-3):246- 61. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 10May;356(19):1915-27. 770) The current and future role of screening in the era of HPV vaccination. Myers E, Huh Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . Pediatr Infect Dis J 2007 Mar;26(3):201-9. 771) The Development of a Cervical Cancer Prevention Program for Underser ved Women in the Dominican Republic . Montgomery K, Montgomery OC. Oncol Nurs Forum 2009 Sep; 36(5):495 -497. Trabajo (s) citado (s): Murillo R . Almonte M Pereira A . Ferrer E . Gamboa . Jeronimo J. Lazcano-Ponce E. Cervical Cancer Screening Programs in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48. 772) The disparity of in diverse LS, al. Oncol 2008 May;109(2):S22-S30. Suppl 1. Trabajo (s) citado (s): 105 Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine just cancer. Myers ER. Am J Obstet Gynecol 2008 May;198(5):487- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 training the knowledge levels and beliefs regarding breast self -examination on women attending a public centre. R. Gozum S. Eur J Oncol Nurs Feb;12(1):58 Trabajo (s) citado (s): Ortega-Altamirano D. L\u00f3pez-Carrillo L. L\u00f3pez-Cervantes M. Estrategias para la ense\u00f1anza del autoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 -25. 775) The efficacy of HPV 16/18 vaccines on sexually active 18 -23 year old women and the impact of HPV vaccination on organized cervical cancer screening. al. Obster Gynecol Scand 2009;88(1):27 -35. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Vaccine Discovery. Koutsky L. Ann Epidemiol 2009 Apr;19(4):239- 44. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . Pediatr J 2007 Mar;26(3):201-9. citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 The Health and Economic Impact of Cervical Cancer Screening and Human Papillomavirus Vaccination in Kidney Transplant Recipients. Wong G, Howard K, Webster A, et al. Transplantation 2009 15Apr;87(7):1078- 91. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Analysis of Online News Stories. Habel MA. Liddon N. et al. J Womens Health of vaccine Vaccine Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine P\u00e9rez G Hern\u00e1ndez-Avila M . Garcia PJ and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8. 782) The human papillomavirus vaccine in Canada. Morris SK, Nguyen CK. Can J Public Health 2008 Mar- Apr;99(2):114- 6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine of vaccine acceptability. Vaccine 2006 31Aug;24(Suppl 3);201- 9. 783) The human papillomavirus Heymann WR. J Am Acad Dermatol 2008 Jun; 58(6):1047- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine programme, Oportunidades, on birthweight . Barber SL, Gertler PJ. Trop Med Int Health 2008 Nov;13(11):1405-14. Trabajo (s) citado (s): Palacio poverty: Mortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325. 785) The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24 . Majewski S, Bosch FX, Dillner J, et al. J Eur Acad Dermatol Venereol 2009 Oct;23(10): 1147-55. Trabajo (s) citado the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due Types DR, Kjaer SK, Sigurdsson K, et al. J Infect Dis 2009 1Apr;199(7):926- 35. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due Types CM, Kjaer SK, Sigurdsson K, et al. J Infect Dis 2009 1Apr;199(7):936- 44. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Cancer Evidence ta Santamar\u00eda Ulloa C. Pobl Salud Mesoam 2009 Jul -Dic;7(1): Trabajo (s) citado (s): L\u00f3pez -Cervantes M. Torres -S\u00e1nchez 789) The Mexican Cancer Trial Self-Sampling for Human Papillomavirus With Cancer 2009 Jan;19(1):27- 32. Trabajo (s) citado (s): Flores Bishai Results Morelos HPV Study . Salud Publica Mex 2003;54(Suppl 3):S388-S398. 790) The new challenges in the prevention of cancer - Introduction. Monsonego J. Vaccine 2008 14Mar;26(Suppl 1):A4-A6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Among Minority Populations. Rogers NM, Cantu AG. J Commun Health 2009 Apr;34(2):135- 43. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Monk Pediatr 2008 Sep;47(7):627- 38. Trabajo (s) citado (s): 107 Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents . Pediatr J 2007 Mar;26(3):201-9. 793) The Pine River Statement: Human Health Consequences of DDT Use. Eskenazi B. et al. Environ Health Perspect 2009 Sep:117(9);1359- 67 Trabajo (s) citado (s): L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L in Australia. Smith MA, Canfell K, Brotherton JML, et al. Int J Cancer 2008 15Oct;123(8):1854- 63. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents and significance of high-risk human papillomavirus DNA test Malaysia and Singapore. SK, YK. Aust New Z Obstet Gynaecol 2009 Jun;49(3):323- 7. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine disease and screening interventions. Pirotta M, Ung L, Stein A, et al. Sex Transm Infect 2009 Dec;85(7):508- 13. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine HPV Vaccination. Haug C. JAMA 2009 19Aug;302(7):795 -6. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazca no-Ponce E. ). Quadrivalent NEJM 2007 10May;356(19):1915-27. The between smoking and age at the menopause: A systematic review . Parente RC, Faerstein E, Celeste RK, et al. Maturitas 2008 20Dec;61(4):287 Trabajo (s) natural women Mexico City . Int J Gynecol Obstet 1996 May;53(2):159-66. 799) The role of body relationship between physical activity and endometrial cancer: from cohort women . Patel AV, Feigelson HS, Talbot JT, et al. Int J Cancer 2008 15Oct;123(8):1877- 82. Trabajo (s) citado (s): Hernandez-Avila M .Case-control physical The other environmental factors in the in Iran - A population based study. Pourfarzi F. et al. Int J Cancer 60 Trabajo (s) citado (s): The HPV -DNA testing in the HPV -induced lesions . Giraldo PC, Eleuterio J Obstet Gynecol Reprod Biol in the Prevention of HIV Infection. Gray RH, Wawer MJ, Serwadda D, et al. J Infect Dis 2009 3. Trabajo (s) citado (s): Vaccarella S . Lazcano-Ponce Castro Schiavon R dietary fa ctors breast cancer: Mexican experience . breast cancer risk in Mexican women . Salud Publica Mex 2008 Mar- Apr;50(2):126-35. Torres-Sanchez L. L\u00f3pez-Carrillo L. Lopez-Cervantes M. Rueda-Neria C, (2000) Food sources of phytoestrogens and -533. -S\u00e1nchez L. Galv\u00e1n -Portillo M. L. (2008) Dietary consumption of phytochemicals and breast cancer in Mex 2997 Jul -Aug;39(4):259 -65. 804) The role of the National Office for Tobacco Control in Mexico. Regalado -Pineda J. Rodr\u00edguez -Ajenjo CJ. Salud Publica Mex S. Valdez-Salgado R . Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo en el IMSS, Morelos. Salud P\u00fablica Mex 2005; 47: 451- 7. Reynales-Shigematsu LM. Costos de atenci\u00f3n m\u00e9dica de las enfermedades atribuibles al consumo de tabaco en las Am\u00e9ricas: revisi\u00f3n de la literatura. Salud Publica Mex 2006;48(supl 1):S190-S200. 805) The vaccine against HPV: the conflict of interest. Laurell AC. Salud Colectiva 2009 Jan-Apr;5(1):127- 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 10May;356(19):1915-27. 806) The war against cervical cancer in Latin America and the Caribbean. Triumph of the scientists. Challenge for the comm unity Foreword . Correa P. Vaccine 2008 19Aug;26(Suppl 11):III -IV Trabajo (s) citado (s): Murillo R . Almonte M Pereira A . Programs in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48. Herrero R Jeronimo J . New Approaches to Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58. Franco EL . Tsu V . Herrero Ponce E. Hildesheim Vaccination and Cervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95. Supplement: Suppl. Vaccines 2009 Sep;8(9):1221- 35. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against human of papillomavirus 16 and a case-control study. J Natl Cancer Inst 2001 1Sep;93(17):1325-30. 109 Villa LL, et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM y m\u00e9todos diagn\u00f3sticos en cancer pulmonary en un centro hospitalario de tercer nivel. Mexico. Gurrola-D\u00edaz CM. et al. Gac Med Mex 2009;145(2):97-101 from lung cancer in Mexico, 1980 -2000. Revista Panamericana de Salud P\u00fablica , 17(4),254 -262. 810) Total Particulate Matter and Study with Histological Insights . S, Ashraf M, Sci 2009 Aug;22(4): 278-87. Trabajo infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. Int Trabajo (s) citado (s): Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian Assessment of Med 2008 22Sep;68(17):1881- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 25Sep;5: Artic 106. Trabajo (s) Mexico . Sex Transm Dis 2005 Oct;32(10):613-8. 814) Treatment of cervical cancer in Italy: Strategies and their impact on the women. De Vincenzo R, Amadio G, Ricci C, et al. Vaccine 2009 29May;27(Suppl 1):A39 -A45. Trabajo (s) citado (s): curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. 815) Treatment patterns and Curr Med Res Opin 2008;24(11):3175-83. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine and incidence data. Shin HR, Park S, Hwang SY, et al. Int J Cancer 2008 15Jan;122(2):393- 97. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Vaccarella S Single-Institution Experience. Konstantinidis IT, Deshpande V, Genevay M, et al. Arch Surg 2009 May;144(5):441- 7. Trabajo (s) citado (s): 110 Lazcano- Ponce EC. JF Danish women. Kjaer Munk C, et al. Sex Transm Dis 2008 Mar;35(3):276- 82. Trabajo (s) citado (s): Franceschi curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV Cancer 2001 1Feb;91(3):412-20. al. Transm Dis 2009 Jun;36(6): 380-6. Trabajo (s) citado (s): Giuliano AR . Lazcano- Ponce E. Villa LL. Flores papillomavirus prevalence and type distribution among men residing in Brazil, and the United S, McIntyre SJ. J School Nurs 2009 Aug;25(4):261- 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Understanding the Reasons Why Mothers Do or Do Not Have Their Adolescent Daughters Vaccinated Against Human Papillomavirus. Dempsey AF, Abraham LM, Dalton V, et al. Ann Epidemiol 2009 Aug;19(8):531- 8. Trabajo (s) citado (s): Lazcano- Ponce Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res 2001 May-Jun;32(3):243-7. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 2008 Jun;75(6):402. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 Uptake two papillomavirus schoolgirls in Manchester: prospective cohort study Brabin SA, Stretch R, et al. BMJ 2008 10May;336(7652):1056- 8. Trabajo (s) citado (s): Zimet 31Aug;24(Suppl 3);201- Upstream Regulatory Found et al. J Virol 2009 1Aug;85(15):7457- 66. Trabajo (s) citado (s): of papillomavirus 16 and a case-control from Study. J. et al. Breast Cancer Res Treat 2009 4Aug. L\u00f3p ez-Carrillo L. Lopez-Cervantes M. Rueda-Neria (2000) Food sources of phytoestrogens and cancer 2009;29(7):583- 9. Trabajo citado HPV: Physicians' and medical students' point of view. de Carvalho NS, Teixeira LM, Pradel EM, et al. Vaccine 2009 5May;27(20):2637- 40. Trabajo (s) citado (s): Lazcano- Ponce E. Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, . Arch Med 2001 May-Jun;32(3):243-7. Zimet GD. vaccine acceptability. Vaccine 16Dec;27:Artic 84 Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine vaccine acceptability. Vaccine 31Aug;24(Suppl 3);201- 9. after transplant: a of recent (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine indications and the cervical screening programme. Heideman DAM, Snijders PJF, Berkhof J, et al. International Journal of Obstetrics and Gynaecology 2008 Jul;115(8):938- 46. Trabajo (s) citado KS . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents J 2007 Mar;26(3):201-9. Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine 8. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine the impact on infection rates. Berchtold A. et al. Int J Public Health OnLine October 2009 Trabajo (s) citado (s): Insinga RP. Dasbach based Vaccine 2007, 26:128-139. 835) Vaccination against the human papilloma virus. All that glitters is not gold. Montes JM, Gomez HN. Atencion Primaria 2008 Jun;40(6):311. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . Block SL . Lazcano-Ponce E Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and adolescents Lehmann C, Benson PAS. Clin Pediatr 2009 Oct;48(8):801- 11. Trabajo (s) citado (s): Villa LL, et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 vaccine in preadolescents and Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . NEJM 2007 10May;356(19):1915-27. Vacuna el virus del papiloma humano. Hern\u00e1ndez WF. Gonz\u00e1lez JH. Universitas Medica 2009 Abr- Jun;50(2):209- 222. Trabajo (s) citado (s): Murillo R . Almonte M Pereira A . . E. Cervical Screening Programs in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48. 840) Vaginal and correlation physician-collected samples. Hess R. Austin RM. et al. Menopause-the Journal of the North American Menopause Society 2008; 15(4): 729. Trabajo (s) citado -D\u00edaz E. Allen B. Leonard YF. Lazcano- Ponce EC. et al. The Acceptability of Self -collected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women's Health & -275. 841) women . Klungsoyr O, Nygard M, Skare G, et al. J Med Screen 2009;16(2):91- 7. Trabajo (s) citado (s): Lazcano- Evaluation model the Mexican national program for early cervical cancer detection and proposals for a new Papillomavirus Testing as Optional Screening Tools Among Latin American Women < 35 and >= 35 Years of Age: Experience from the Latin American Screening Study . Syrjanen K, Derchain S, Roteli-Martins C, et al. Acta Cytologica 2008 Nov-Dec;52(6):641- 53. Trabajo (s) citado (s): A P . Uribe M . Manzanares H . Antunez A. State, Mexico . Cancer Causes Control 2003 Aug;14(6):505-12. 113 843) Value human papillomavirus vaccination in M. 17Apr;134(Suppl 2):S95-S99. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Vaccine Acceptance by Men. Ferris DG, Waller JL, Miller J, et al. J Am Board Fam Med 2009 Jan-Feb;22(1):34- 42. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM menopause among women natural women Mexico City Oct;8(10):1379- 98. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine relation to risk of endometrial cancer: A systematic review of the literature . McCullough ML, Bandera EV, Moore DF, et al. Prev Med 2008 Apr;46(4):298- 302. Trabajo (s) citado Int J Gynecol Cancer 2005 Sep -Oct;15(5 ):938 Vitamin Cancer Prevention: Global Perspective . Garland CF, Gorham ED, Mohr SB, et al. Ann Epidemiol 2009 Jul;19(7):468- 83. Trabajo (s) Int J Gynecol Cancer E intake and and gastric cancers in the NIH-AARP Diet and Health Study. Carman S. et al. Int J Cancer 2009;125:165- 70 Trabajo (s) citado (s): 83: 601- 850) Vitamin supplement breast cancer: the Shanghai Breast Study. Breast Cancer Sep;111:269- 78 Trabajo (s) citado Lajous M. Romieu I. Sabia S. and postmenopausal prospective of women. Control 17, 1209 (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine . NEJM 2007 10May;356(19):1915-27. What Women With Abnormal Pap or Positive HPV Tests? Hoover K, Friedman A, Montano D, et al. Sex Transm Dis 2009 Mar;36(3):141- 6. Trabajo (s) citado (s): introduction of an HPV vaccine? Mun\u00f3z N, Jacquard AC. Press Med 2008 Oct;37(10):1377-90. Trabajo (s) citado (s): Vaccarella S infection: pooled analysis of the International Agency for Research Cancer HPV Prevalence Surveys. , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677-2684. Vaccarella S 9. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Lynge E, Antilla A, Arbyn M, et al. Eur J Cancer 2009 Oct;45(15):2714 -21. Sp. Iss . SI. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 10May;356(19):1915-27. Why be a common cause of prostate and breast cancers in the French Caribbean Island, Martinique. overview on key mechanisms of pesticide-induced cancer . Pharmacother 2009 vaccination against human papillomavirus prevent eye disease? A review of the evidence. Hughes DS, Powell N, Fiander AN. Br J Ophthalmol 2008 Apr;92(4):460- 5. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine NEJM 2007 10May;356(19):1915-27. Women in Mexico : challenges to well -being. DiGirolamo AM. Salgado -de Snyder N. Salud Publica Mex 2008 Nov -Dic;50(16):516 -22 Trabajo (s) citado (s): Ortega-Altamirano D. L\u00f3pez-Carrillo L. L\u00f3pez-Cervantes M. Estrategias para la ense\u00f1anza del autoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 -25. L\u00f3pez-Carrillo L . Torres-S\u00e1nchez L . L\u00f3pez-Cervantes M. et al. Identificaci\u00f3n de lesiones mamarias en M\u00e9xico. Salud P\u00fablica de M\u00e9xico 2001;43(3):199 -202. 859) Women show mixed intentions regarding the R, et al. Eur J Cancer 2008 Jun;44(9):1186- 92. Trabajo (s) citado (s): Lazcano- Ponce Rivera (HPV) vaccine among mothers of adolescents in Cuernavaca, . Arch Med 2001 May-Jun;32(3):243-7. Zimet GD. of vaccine Vaccine 2006 31Aug;24(Suppl 3);201- 9. 115 860) Women's participation in a cervical cancer screening program in northern Peru . Winkler J, Bingham A, Coffey P, et al. Health Educ Res 2008 Feb;23(1):10-24. Trabajo (s) citado (s): Lazcano-Ponce EC . Najera Aguilar P . Buiatti Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The cervical cancer screening program Mexico: problems . Allen B P . De Ruiz of Mexico J Womens Health 1999 Apr;8(3):399- 408. 861) Worldwide Impact of the Human Papillomavirus Vaccine. Hakim AA, Dinh TA. Curr Treat Opt Oncol 2009 Apr;10(1-2):44- 53. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine women\" - extending the human papillomavirus vaccine population base. Marshall HS, Isaacs D. Med J Austr 2008 3Nov;189(9):527. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine against the papillomavirus GV. Med J Austr 2008 5May;188(9):501- 2. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Shanghai, China. Xue YZ, Zhang WY, al. Eur J Obstet Gynecol Reprod Biol 2009 Aug;145(2):214- 8. curves of human papillomavirus prevalence in women worldwide : et al. Int J Cancer 2006 1Dec;119(11):2677- 2684. 865) 2008 Thomas Parran Award Lecture: Translational Research, STD Control, and Health Disparities A Challenge and an Opportunity. Hook EW. Sex Transm Dis 2008 Dec;35(12):969- 72. Trabajo (s) citado (s): Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ). Quadrivalent vaccine Trabajo (s) (s): 116 Imagen: upload.wikipedia.org MAR\u00cdA EVA DUARTE DE PER\u00d3N 1919 - 1952 Eva per\u00f3n contaba con 33 a\u00f1os cuando el 26 de julio de 1952 el c\u00e1ncer cervical puso fin a su vida, \"Evita\" como le dec\u00edan de cari\u00f1o sus seguidores en Argentina contrajo esta terrible enfermedad en 1950 a la edad de 31 a\u00f1os, en ese tiempo el m\u00e9todo de detecci\u00f3n temprana de c\u00e1ncer cervical creado por el Dr. Papanicolaou no era una pr\u00e1ctica com\u00fan, a\u00fan y cuando esta prueba se comenzara a promover en este pa\u00eds en 1946. El presidente de Argentina, el Coronel Juan Domingo Per\u00f3n esposo de Eva le encomend\u00f3 al cirujano neoyorquino George Pack que dirigiera la histerectom\u00eda en noviembre de 1951, despu\u00e9s se confirmar\u00eda a trav\u00e9s de unos apuntes del propio Pack que Eva Per\u00f3n nunca supo que padec\u00eda c\u00e1ncer cervical tampoco de lo grave del caso y ni siquiera conoci\u00f3 al medico que la oper\u00f3, quiz\u00e1 por razones pol\u00edticas o por alguna otra dif\u00edcil de explicar, lo cierto es que el c\u00e1ncer cervicouterino cobraba una vida m\u00e1s en esta ocasi\u00f3n la de una de las mujeres m\u00e1s emblem\u00e1ticas de todos los tiempos en Argentina y quiz\u00e1 de todo el mundo. Lerner BH. The illness and death of Eva Per\u00f3n: cancer, politics and secrecy. The Lancet 2000 3Jun;355:1988- 91 117 INSTITUTO NACIONAL DE SALUD P\u00daBLICA CENTRO DE INVESTIGACI\u00d3N EN SALUD POBLACIONAL Dr. Eduardo C\u00e9sar Lazcano Ponce Director Ejecutivo Dr. Ruy L\u00f3pez Ridaura Jefe de la Unidad de Investigaci\u00f3n en Diabetes y Riesgo Cardiovascular Documento de An\u00e1lisis Citogr\u00e1fico preparado por: C.D. Daniel Angel Acu\u00f1a Montesinos C.D. Silvia Leonor Rojas Mart\u00ednez Apoyo a la Investigaci\u00f3n Unidad de Investigaci\u00f3n en Diabetes y Riesgo Cardiovascular CISP-INSP. Instituto Nacional de "}